<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">93423</article-id><article-id pub-id-type="doi">10.7554/eLife.93423</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.93423.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title><italic>Bacillus velezensis</italic> HBXN2020 alleviates <italic>Salmonella</italic> Typhimurium infection in mice by improving intestinal barrier integrity and reducing inflammation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Linkang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Haiyan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xinxin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Mengyuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Dongyang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Dayue</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Zhixuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Xiangmin</given-names></name><email>lixiangmin@mail.hzau.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qian</surname><given-names>Ping</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3120-2556</contrib-id><email>qianp@mail.hzau.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023b72294</institution-id><institution>National Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Huazhong Agricultural University</institution></institution-wrap><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023b72294</institution-id><institution>College of Veterinary Medicine, Huazhong Agricultural University</institution></institution-wrap><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Key Laboratory of Preventive Veterinary Medicine in Hubei Province, the Cooperative Innovation Center for Sustainable Pig Production</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03rp50x72</institution-id><institution>University of the Witwatersrand</institution></institution-wrap><country>South Africa</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>11</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP93423</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-11-21"><day>21</day><month>11</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-11-21"><day>21</day><month>11</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.11.21.568052"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-12"><day>12</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.93423.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-06-05"><day>05</day><month>06</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.93423.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-11"><day>11</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.93423.3"/></event></pub-history><permissions><copyright-statement>© 2024, Wang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-93423-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-93423-figures-v1.pdf"/><abstract><p><italic>Bacillus velezensis</italic> is a species of <italic>Bacillus</italic> that has been widely investigated because of its broad-spectrum antimicrobial activity. However, most studies on <italic>B. velezensis</italic> have focused on the biocontrol of plant diseases, with few reports on antagonizing <italic>Salmonella</italic> Typhimurium infections. In this investigation, it was discovered that <italic>B. velezensis</italic> HBXN2020, which was isolated from healthy black pigs, possessed strong anti-stress and broad-spectrum antibacterial activity. Importantly, <italic>B. velezensis</italic> HBXN2020 did not cause any adverse side effects in mice when administered at various doses (1×10<sup>7</sup>, 1×10<sup>8</sup>, and 1×10<sup>9</sup> CFU) for 14 days. Supplementing <italic>B. velezensis</italic> HBXN2020 spores, either as a curative or preventive measure, dramatically reduced the levels of <italic>S.</italic> Typhimurium ATCC14028 in the mice’s feces, ileum, cecum, and colon, as well as the disease activity index (DAI), in a model of infection caused by this pathogen in mice. Additionally, supplementing <italic>B. velezensis</italic> HBXN2020 spores significantly regulated cytokine levels (<italic>Tnfa</italic>, <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Il10</italic>) and maintained the expression of tight junction proteins and mucin protein. Most importantly, adding <italic>B. velezensis</italic> HBXN2020 spores to the colonic microbiota improved its stability and increased the amount of beneficial bacteria (<italic>Lactobacillus</italic> and <italic>Akkermansia</italic>). All together, <italic>B. velezensis</italic> HBXN2020 can improve intestinal microbiota stability and barrier integrity and reduce inflammation to help treat infection by <italic>S.</italic> Typhimurium.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>Bacillus velezensis</italic></kwd><kwd>antibacterial activity</kwd><kwd><italic>S</italic>. Typhimurium infection</kwd><kwd>infections</kwd><kwd>gut health</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>S. enterica</italic> serovar Typhi</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>National Program on Key Research Project of China</institution></institution-wrap></funding-source><award-id>2021YFD1800300</award-id><principal-award-recipient><name><surname>Qian</surname><given-names>Ping</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007925</institution-id><institution>Yingzi Tech Huazhong Agricultural University Intelligent Research Institute of Food Health</institution></institution-wrap></funding-source><award-id>IRIFH202209</award-id><principal-award-recipient><name><surname>Qian</surname><given-names>Ping</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012226</institution-id><institution>Fundamental Research Funds for the Central Universities</institution></institution-wrap></funding-source><award-id>2662016PY004</award-id><principal-award-recipient><name><surname>Qian</surname><given-names>Ping</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>National Program on Key Research Project of China</institution></institution-wrap></funding-source><award-id>2022YFD1800800</award-id><principal-award-recipient><name><surname>Qian</surname><given-names>Ping</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007925</institution-id><institution>Yingzi Tech Huazhong Agricultural University Intelligent Research Institute of Food Health</institution></institution-wrap></funding-source><award-id>IRIFH202301</award-id><principal-award-recipient><name><surname>Qian</surname><given-names>Ping</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value><italic>Bacillus velezensis</italic> has broad-spectrum antibacterial activity and can reduce the colonization of <italic>Salmonella</italic> Typhimurium in the intestinal tract of mice.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p><italic>Salmonella</italic> Typhimurium (<italic>S</italic>. Typhimurium) is a major foodborne zoonotic pathogen that can cause diarrhea and colitis in humans and animals (<xref ref-type="bibr" rid="bib15">Fàbrega and Vila, 2013</xref>; <xref ref-type="bibr" rid="bib59">Yang et al., 2021</xref>). According to reports, <italic>Salmonella</italic> infections are common in both industrialized and developing nations, posing a serious risk to public health and resulting in significant financial losses (<xref ref-type="bibr" rid="bib24">Katiyo et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Mohan et al., 2019</xref>). At present, antibiotics remain one of the most effective treatment strategies for <italic>Salmonella</italic> infections. However, numerous studies have reported that the prolonged use or misuse of antibiotics can lead to environmental pollution, an increase in multi-drug-resistant bacteria, as well as gastrointestinal microbiota dysbiosis (<xref ref-type="bibr" rid="bib16">Ferri et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Paulson and Zaoutis, 2015</xref>; <xref ref-type="bibr" rid="bib40">Reyman et al., 2022</xref>). In order to tackle <italic>Salmonella</italic> infections, a hunt for novel antimicrobial drugs is now underway.</p><p>More research has recently demonstrated the critical role gut microbiota plays in reducing intestinal inflammation (<xref ref-type="bibr" rid="bib9">Cristofori et al., 2021</xref>) and mending the intestinal barrier (<xref ref-type="bibr" rid="bib34">Ohland and Macnaughton, 2010</xref>; <xref ref-type="bibr" rid="bib55">Wang et al., 2020</xref>). The use of probiotics is a popular approach to modulating intestinal microbiota nowadays. Among all probiotics, <italic>Bacillus</italic> is one of the most popular probiotic species because of its ability to form endospores that survive gastric transit, storage, and delivery conditions (<xref ref-type="bibr" rid="bib19">Gu et al., 2015</xref>). Furthermore, <italic>Bacillus</italic> species can generate extracellular enzymes and antimicrobial metabolites that inhibit enteric pathogens, which lowers the risk of infection and enhances nutrient utilization (<xref ref-type="bibr" rid="bib1">Abdhul et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Ouattara et al., 2017</xref>).</p><p>Recent studies have found that <italic>Bacillus velezensis</italic> (<italic>B. velezensis</italic>) has the enormous potential to produce a variety of metabolites with broad-spectrum antibacterial activity (<xref ref-type="bibr" rid="bib61">Ye et al., 2018</xref>). Meanwhile, previous studies have reported that <italic>B. velezensis</italic> exhibits varying degrees of beneficial effects on plants, livestock, poultry and fish. For instance, the combined use of <italic>B. velezensis</italic> SQR9 mutant and FZB42 improved root colonization and the production of secondary metabolites that are beneficial to cucumber (<xref ref-type="bibr" rid="bib46">Shao et al., 2022</xref>). <italic>B. velezensis</italic> isolated from yaks was shown to enhance growth performance and ameliorate blood parameters related to inflammation and immunity in mice (<xref ref-type="bibr" rid="bib27">Li et al., 2019</xref>). The dietary <italic>B. velezensis</italic> supplementation can regulate the innate immune response in the intestine of crucian carp and reduce the degree of intestinal inflammation damage induced by <italic>Aeromonas veronii</italic> (<xref ref-type="bibr" rid="bib63">Zhang et al., 2019</xref>). However, studies on <italic>B. velezensis</italic> in the prevention of <italic>S</italic>. Typhimurium infection are rarely reported; instead, the majority of investigations on <italic>B. velezensis</italic> focused on the biocontrol of fungal infections in plants. In this study, a strain of <italic>B. velezensis</italic> HBXN2020 with broad-spectrum antibacterial activity against <italic>Salmonella</italic> was selected from a vast number of <italic>Bacillus</italic> strains. Next, we evaluated its safety in mice by supplementing <italic>B. velezensis</italic> HBXN2020 and then explored the protective effects in STm-infected mice. Notably, <italic>B. velezensis</italic> HBXN2020 alleviated colon tissue damage caused by STm infection, as indicated by markers such as STm loads, <italic>Tnfa</italic> and <italic>Tjp1</italic> levels. Moreover, supplementing <italic>B. velezensis</italic> HBXN2020 also increased the abundance of beneficial bacteria, specifically <italic>Lactobacillus</italic> and <italic>Akkermansia</italic>, within the colon microbiota. As a result, this research supports the creation of probiotic-based microbial products as a substitute method of preventing <italic>Salmonella</italic> infections.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Isolation of <italic>Bacillus</italic></title><p>Four strains of <italic>Bacillus</italic> with antibacterial activity were screened from a large amount of presumptive <italic>Bacillus</italic> isolates, based on spot-on-plate tests analysis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), and the four strains clearly displayed the properties of bacteria in the genus <italic>Bacillus</italic> such as colonies were crateriform, Gram-positive, rod shape, and endospore-forming ability. Next, a comparative analysis of the antibacterial spectrum of four strains of <italic>Bacillus</italic> found that one strain exhibited excellent antibacterial activity against common pathogens (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Therefore, this strain was selected in this study for further research, which was designated as the HBXN2020.</p></sec><sec id="s2-2"><title>Growth curve and in vitro resistance against environmental assaults</title><p>The growth of HBXN2020 was assessed in flat-bottomed 100-well microtiter plates by measuring the values of OD<sub>600</sub> every hour using an automatic growth curve analyzer. After measurement, we found that HBXN2020 entered the logarithmic growth phase after 2 hr, and reached a plateau after 10 hr of culture (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Growth curve of <italic>B. velezensis</italic> HBXN2020 and its in vitro resistance against environmental assaults.</title><p>(<bold>A</bold>) Growth curves of <italic>B. velezensis</italic> HBXN2020 cultured in Luria-Bertani (LB) medium at 37°C, detection of OD<sub>600</sub> values at 1 hr intervals in microplate reader. (<bold>B</bold>) Survival rate of endospore and vegetative cells of <italic>B. velezensis</italic> HBXN2020 after 30 min at different temperatures (37°C, 45°C, 55°C, 65°C, 75°C, 85°C, or 95°C). Equal amounts of endospore and vegetative cells of HBXN2020 were exposed to the following: (<bold>C</bold>) acid solution (pH 2–7), (<bold>D</bold>) 0.3% bile salts, (<bold>E</bold>) simulated gastric fluid (SGF) (pH 1.2) supplemented with pepsin, and (<bold>F</bold>) simulated intestinal fluid (SIF) (pH 6.8) containing trypsin at 37°C. At predetermined time points, 100 μL was taken from each sample, and 10-fold serially diluted with sterile PBS (pH 7.2), and then spread on LB agar plates and cultured at 37°C for 12 hr before bacterial counting. Each group was repeated three times (n=3).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig1">Figure 1A–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Spot-on-plate assay of <italic>Bacillus</italic>.</title><p>(<bold>A</bold>) and (<bold>E</bold>) indicator bacteria are <italic>Staphylococcus aureus</italic> S18; (<bold>B</bold>) and (<bold>F</bold>) indicator bacteria are <italic>S. aureus</italic> S18+; (<bold>C</bold>) and (<bold>G</bold>) indicator bacteria are <italic>Salmonella</italic> SA083 (<italic>S</italic>. Enteritidis SE006); (<bold>D</bold>) and (<bold>H</bold>) indicator bacteria are <italic>Escherichia coli</italic> EC16 (<italic>E. coli</italic> EC016). FS: fermentation supernatant; BL: bacteria liquid.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>PDF file containing original <italic>Bacillus</italic> antibacterial screening images for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Original files for antibacterial screening of <italic>Bacillus</italic> displayed in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig1-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Next, we evaluated the effect of physical, chemical, and biological sterilization conditions such as high temperature, strong acidity, and enzyme preparation on the survival of HBXN2020. The survival rate of HBXN2020 showed a decreasing trend with increasing temperature (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), but this decrease was not obvious. In a strong acid environment (pH 2.0), HBXN2020 maintained a high survival rate (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), suggesting that HBXN2020 spores can survive under extreme conditions. Based on these results, we hypothesized that HBXN2020 spores might also exhibit improved survival in gastrointestinal tract environments. Therefore, we further evaluated the survival rate of HBXN2020 in bile salt (0.3%, vol/vol), simulated gastric fluid (pepsin 1 mg/mL, pH 1.2), and simulated intestinal fluid (trypsin 1 mg/mL, pH 6.8). As shown in <xref ref-type="fig" rid="fig1">Figure 1D–F</xref> (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), HBXN2020 spores demonstrated significantly improved tolerance to these simulated gastrointestinal tract environments.</p></sec><sec id="s2-3"><title>Antibiotic susceptibility of HBXN2020 and bacteriostasis effect in vitro</title><p>In order to assess HBXN2020’s drug resistance, 19 antibiotics that are frequently used in clinical settings were chosen in this study. The results indicated that only polymyxin B had a relatively small inhibition zone diameter (less than 15 mm). Ampicillin, meropenem, minocycline, ofloxacin, and trimethoprim had the strongest inhibition on HBXN2020, with an inhibition zone diameter exceeding 30 mm (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). This indicated that HBXN2020 was extremely sensitive to β-lactams, tetracyclines, and quinolone drugs. We next utilized an in vitro antibacterial assay to evaluate the antibacterial activity of HBXN2020. The results showed that HBXN2020 had a similar inhibitory effect on standard and wild strains of <italic>E. coli</italic>, <italic>Salmonella</italic>, <italic>S. aureus</italic>, and <italic>Clostridium perfringens</italic> (<italic>C. perfringens</italic>), as well as wild strains of <italic>Streptococcus suis</italic> (<italic>S. suis</italic>), <italic>Pasteurella multocida</italic> (<italic>P. multocida</italic>), and <italic>Actinobacillus pleuropneumoniae</italic> (<italic>A. pleuropneumoniae</italic>). Except for the wild strains of <italic>S. suis</italic> and <italic>A. pleuropneumoniae</italic>, the diameter of the inhibition zone of other strains was above 15 mm (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, and <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>), while the size of the inhibition zone of <italic>S. suis</italic> and <italic>A. pleuropneumoniae</italic> was also more than 12 mm.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Antibiotic susceptibility of <italic>B. velezensis</italic> HBXN2020 and bacteriostasis assay in vitro.</title><p>(<bold>A</bold>) The diameter of the antibacterial zone indicates the extent of sensitivity to antibiotics. (<bold>B</bold>) The diameter of the antibacterial zone indicates the extent of inhibition against pathogenic bacteria. The diameter of the antibacterial zone was measured with vernier caliper. Each group was repeated three times (n=3). R, resistant; I, moderately sensitive; S, sensitive.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig2">Figure 2A and B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>In vitro antibacterial test of <italic>B.</italic> <italic>velezensis</italic> HBXN2020.</title><p>The in vitro antagonistic activity of <italic>B. velezensis</italic> HBXN2020 against 18 indicator strains (pathogens) was tested using agar well-diffusion method. The fermentation supernatant of <italic>B. velezensis</italic> HBXN2020 was filtered with a 0.22 μm filter and add it to different Oxford cups. All plates were cultured at 37°C for 16 hr before observing the inhibition zone, and the diameter of the inhibition zone was measured by vernier caliper. The clear zone was expressed the antagonistic activity.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>PDF file containing original <italic>B</italic>. <italic>velezensis</italic> HBXN2020 cell-free supernatant (CFS) antibacterial images for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original files for <italic>B</italic>. <italic>velezensis</italic> HBXN2020 cell-free supernatant (CFS) antibacterial images displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Genomic characteristics</title><p>HBXN2020’s complete genome was sequenced using the Illumina HiSeq and PacBio platforms. The results showed that HBXN2020 has a circular chromosome of 3,929,792 bp (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) with a GC content of 46.5%, including 3744 protein-coding genes (coding sequence [CDS]), 86 tRNA genes, and 27 rRNA genes (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Furthermore, the HBXN2020 genome also contains 13 different clusters of secondary metabolic synthesis genes, such as Fengycin (genomic position: 1,865,856) and Difficidin (genomic position: 2,270,091) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Genomic characteristics and phylogenetic relationships of <italic>B. velezensis</italic> HBXN2020.</title><p>(<bold>A</bold>) The whole-genome map of <italic>B. velezensis</italic> HBXN2020 with its genomic features. The map consists of six circles. From the inner circle to the outer circle: (1) GC-skew, (2) GC content, (3) reverse protein-coding genes, different colors represent different COG functional classifications, (4) genes transcribed in reverse direction, (5) genes transcribed in forward direction, (6) forward protein-coding genes, different colors represent different COG functional classifications. (<bold>B</bold>) The whole-genome phylogenetic tree was constructed based on genome-wide data from 14 <italic>Bacillus</italic> strains. <italic>B. velezensis</italic> HBXN2020 are indicated in bold.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>B.</italic> <italic>velezensis</italic> HBXN2020 genome average nucleotide identity (ANI) analysis.</title><p>The heatmap based on the ANI based on the BLAST (ANIb) value of strain HBXN2020 and other <italic>Bacillus</italic> species. The <italic>B. velezensis</italic> HBXN2020 was labeled in red letters.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig3-figsupp1-v1.tif"/></fig></fig-group><p>A phylogenetic tree based on genome-wide data from all 14 <italic>Bacillus</italic> strains demonstrated that the HBXN2020 belongs to the <italic>B. velezensis</italic> species (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To further understand the classification status of HBXN2020, the online tool JSpeciesWS was used to calculate the average nucleotide identity (ANI) based on the BLAST (ANIb) method. As shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, HBXN2020 was found to be a member of the <italic>B. velezensis</italic> species due to the high percentage of ANIb (more than 97%).</p></sec><sec id="s2-5"><title>Safety evaluation of <italic>B. velezensis</italic> HBXN2020</title><p>We assessed the in vivo effects of <italic>B. velezensis</italic> HBXN2020 in a mouse model in order to ascertain its safety. After gavage with <italic>B. velezensis</italic> HBXN2020 spores for 2 weeks, we observed no significant difference in the body weight of each group of mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). The gene expression levels of <italic>Tnfa</italic>, <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Il10</italic> of colon from all groups of mice exhibited no remarkable changes (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). However, in the colon, mRNA levels of the barrier proteins <italic>Tjp1</italic> and <italic>Ocln</italic> were trending toward an increase compared with the control group (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). Additionally, blood routine tests and serum biochemistry tests were performed for mice in the control group and H-HBXN2020 group on the 14th day after oral administration of <italic>B. velezensis</italic> HBXN2020 spore multiple times. As shown in <xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, the blood parameters of mice after <italic>B. velezensis</italic> HBXN2020 spores treatment, including red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), hemoglobin (HGB), white blood cells (WBC), platelets (PLT), hematocrit (HCT), and mean corpuscular hemoglobin concentration (MCHC), were consistent with those of healthy mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig4s1sdata1">Figure 4—figure supplement 1—source data 1</xref>). The serum biochemical parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBIL), serum creatinine (CREA), and blood urea nitrogen (BUN), were also within normal limits (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). The corresponding histological analysis of colon tissue from mice receiving low, medium, and high doses of <italic>B. velezensis</italic> HBXN2020 spores (L-HBXN2020, M-HBXN2020, and H-HBXN2020 groups, respectively) is presented in <xref ref-type="fig" rid="fig4">Figure 4F</xref>. The colon tissue sections of mice in the test groups showed no significant differences compared to the control group. Additionally, there were no observable differences in the major organ tissues (heart, liver, spleen, lung, and kidney) of mice treated with the high dose of <italic>B. velezensis</italic> HBXN2020 spores compared to healthy mice (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). The results of this trial show that <italic>B. velezensis</italic> HBXN2020 is safe to use and has no negative side effects in mice.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>In vivo safety evaluation of <italic>B. velezensis</italic> HBXN2020 in a mouse model.</title><p>(<bold>A</bold>) Body weights changes of mice during gavage with <italic>B. velezensis</italic> HBXN2020 spores. Mice were treated with sterile PBS (control group) or low-dose (L-HBXN2020 group), medium dose (M-HBXN2020 group), and high-dose (H-HBXN2020 group) of <italic>B. velezensis</italic> HBXN2020 spores. Weighing and gavage were performed once every 2 days during the experimental period (15 days). Data were shown as mean values ± SEM (n=5). (<bold>B</bold>) The mRNA levels of inflammatory cytokines in the colon of mice measured by RT-qPCR. Data were shown as mean values ± SEM (n=5). (<bold>C</bold>) The mRNA levels of barrier protein <italic>Tjp1</italic>, <italic>Ocln</italic>, <italic>Cldn1,</italic> and <italic>Muc2</italic> in the colon of mice measured by RT-qPCR. Data were shown as mean values ± SEM (n=5). (<bold>D</bold>) Major blood routine parameters and (<bold>E</bold>) serum biochemical parameters of mice in the control group and H-HBXN2020 group. Data were shown as mean values ± SEM (n=3). (<bold>F</bold>) Hematoxylin and eosin (H&amp;E) stained colon sections in the different groups. Scale bar: 200 μm.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig4">Figure 4A–E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Hematological parameters.</title><p>Blood routine parameters of mice in the control group and high-dose <italic>B. velezensis</italic> HBXN2020 group. (<bold>A</bold>) Hematocrit (HCT), (<bold>B</bold>) mean corpuscular hemoglobin concentration (MCHC).</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A and B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Hematoxylin and eosin (H&amp;E) staining of the intestine, heart, liver, spleen, lung, and kidney.</title><p>Tissues were obtained from mice in the high-dose <italic>B. velezensis</italic> HBXN2020 group at 15 days. PBS was used as a control. Scale bars: 100 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig4-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Oral administration of <italic>B. velezensis</italic> HBXN2020 spores alleviated infection by <italic>S</italic>. Typhimurium</title><p>Testing both solid and liquid co-culture methods to see if <italic>B. velezensis</italic> HBXN2020 might suppress <italic>S</italic>. Typhimurium ATCC14028 (STm), the findings indicated that <italic>B. velezensis</italic> HBXN2020 decreased the development of STm in a dose-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, and <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref>). Next, the therapeutic potential of <italic>B. velezensis</italic> HBXN2020 was evaluated in an STm-infected mouse model. At days 1, 3, and 5 after STm infection, mice in the STm+HBXN2020 group and HBXN2020 group were orally administered <italic>B. velezensis</italic> HBXN2020 spores by gavage, STm+CIP group were given oral ciprofloxacin, while the control group and STm+PBS group were orally treated with sterile PBS (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Also, the number of excreted STm in feces was counted daily at the designated time points. As shown in <xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, there was a significant and continuous reduction in the number of STm in feces following treatment with <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin, while the number of <italic>B. velezensis</italic> HBXN2020 viable bacteria in feces is also gradually decreasing (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig5s2sdata1">Figure 5—figure supplement 2—source data 1</xref>). The number of STm in the mice feces of STm+HBXN2020 group and STm+CIP group exhibited a reduction ranging from 0.12 to 1.18 logs and 0.76–1.81 logs, respectively, compared with the STm+PBS group, over the period from day 2 to day 7 post-treatment. Moreover, treatment with <italic>B. velezensis</italic> HBXN2020 spore or ciprofloxacin resulted in a 1.06, 1.69, 1.14 logs and 1.70, 2.15, 1.48 logs reduction in the number of STm in the cecum, colon, and ileum, respectively (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, and <xref ref-type="supplementary-material" rid="fig5s2sdata1">Figure 5—figure supplement 2—source data 1</xref>). The weight loss (p&lt;0.05) and disease activity index (DAI) scores (p&lt;0.01) were significantly reduced in mice after <italic>B. velezensis</italic> HBXN2020 spore treatment or ciprofloxacin treatment compared to that in the PBS treatment group (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). In addition, we also measured the colon length of the mice and found that the STm+PBS group had a significantly shorter colon length (p&lt;0.001) than the control group and HBXN2020 group. However, compared to the STm+PBS group, the STm+HBXN2020 group (p&lt;0.05) and STm+CIP group exhibited a longer colon (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Oral <italic>B. velezensis</italic> HBXN2020 spores alleviated infection by <italic>S</italic>. Typhimurium.</title><p>(<bold>A</bold>) In vitro bacterial competition between STm and <italic>B. velezensis</italic> HBXN2020. STm were co-incubated with <italic>B. velezensis</italic> HBXN2020 at various ratios at 37°C with shaking. The growth of STm was reflected by bacterial counting per hour. (<bold>B</bold>) Experimental design for treatment in this study. Orally administrated with either sterile PBS, <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin by gavage at days 1, 3, and 5 after STm (5×10<sup>7</sup> CFU/mouse) infection, respectively. All mice were euthanized at day 7 after STm infection. (<bold>C</bold>) Bacterial count of STm in mouse feces. Fecal samples were collected per day after STm infection and resuspended in sterile PBS (0.1 g of fecal resuspended in 1 mL of sterile PBS). One hundred microliters of each sample performed a serial of 10-fold dilutions and spread on selective agar plates (50 µg/mL kanamycin) and incubated at 37°C for 12 hr before bacterial counting. The bacterial loads of STm in (<bold>D</bold>) cecum and (<bold>E</bold>) colon. The cecum and colon were harvested and then homogenized. Data were shown as mean values ± SEM (n=6). Statistical significance was evaluated using Student’s t-test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001). (<bold>F</bold>) Daily body weight changes and (<bold>G</bold>) daily disease activity index (DAI) scores of mice with different treatment groups. Data were shown as mean values ± SEM (n=6). Statistical significance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001). (<bold>H</bold>) Colonic tissue images. (<bold>I</bold>) The length of the colon from per group (n=6). Statistical significance was evaluated using one-way ANOVA with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig5">Figure 5A, C, D, E, F, G, I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>PDF file containing original colonic tissue image for <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Original files for colonic tissue image displayed in <xref ref-type="fig" rid="fig5">Figure 5H</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig5-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>In vitro antagonistic activity of <italic>B. velezensis</italic> HBXN2020 against <italic>S</italic>. Typhimurium ATCC14028 in liquid and solid media.</title><p>The antagonistic <italic>Salmonella</italic> activities of HBXN2020 cell-free supernatant (CFS) were determined using spot-on lawn assay (<bold>A</bold>) and agar well-diffusion assay (<bold>B</bold>). (<bold>C</bold>) Diameter of inhibition zone in the spot-on lawn assay and agar well-diffusion assay. Data were shown as mean values ± SEM (n=3). Each group was repeated three times. AMP+, ampicillin as a positive control, LB medium as a negative control. ND, no detectable. (<bold>D</bold>) <italic>S</italic>. Typhimurium ATCC14028 (STm) were co-incubated with <italic>B. velezensis</italic> HBXN2020 in LB medium at various ratios at 37°C. The survivals of STm were examined at indicated time points by bacterial counting on selective agar plates. Data were shown as mean values ± SEM (n=3). Statistical significance was evaluated using Student’s t-test. *, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>PDF file containing original <italic>B</italic>. <italic>velezensis</italic> HBXN2020 and its cell-free supernatant (CFS) inhibited STm images for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1 and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata3"><label>Figure 5—figure supplement 1—source data 3.</label><caption><title>Original files for antibacterial images of <italic>B</italic>. <italic>velezensis</italic> HBXN2020 and its cell-free supernatant (CFS) against STm displayed in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig5-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>The effect of therapeutic <italic>B.</italic> <italic>velezensis</italic> HBXN2020 on the bacterial load in feces of mice and the histological score of the colons.</title><p>(<bold>A</bold>) The bacterial load of <italic>B. velezensis</italic> HBXN2020 in mouse feces. The quantity of <italic>B. velezensis</italic> HBXN2020 was identified by combining bacterial count and PCR (n=5). Data were shown as mean values ± SEM. (<bold>B</bold>) The bacterial loads of <italic>S</italic>. Typhimurium ATCC14028 in ileum. The ileum was harvested and then homogenized. One hundred microliters of each sample performed a serial of 10-fold dilutions and spread on selective agar plates and incubated at 37°C for 12 hr before bacterial counting. Data were shown as mean values ± SEM (n=6). Statistical significance was evaluated using Student’s t-test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001). (<bold>C</bold>) Histological scores of colons (n=3). (<bold>D</bold>) <italic>B. velezensis</italic> HBXN2020 single colony PCR identification results. Statistical significance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig5-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig5-figsupp2-v1.tif"/></fig></fig-group><p>Histological analysis further showed that in the control group and HBXN2020 group, the colon epithelial cells and crypt structure were intact with neat villi, while STm+PBS group showed significant histological damage, including erosion or loss of the intestinal epithelium, crypt destruction, and inflammatory cell infiltration in the colonic tissues (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Compared with the STm+PBS group, <italic>B. velezensis</italic> HBXN2020 and ciprofloxacin protected the mucosal architecture and the loss of intestinal epithelial cells, and reduced inflammatory cell infiltration (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Oral <italic>B. velezensis</italic> HBXN2020 spores attenuated colonic damage and inflammatory reaction.</title><p>(<bold>A</bold>) Hematoxylin and eosin (H&amp;E) stained colon tissue sections. Scale bar: 50 μm. The mRNA levels of (<bold>B</bold>) <italic>Tnfa</italic>, (<bold>C</bold>) <italic>Il1b</italic>, (<bold>D</bold>) <italic>Il6</italic>, and (<bold>E</bold>) <italic>Il10</italic> were detected by RT-qPCR. Data were shown as mean values ± SEM (n=5). The mRNA levels of (<bold>F</bold>) <italic>Tjp1</italic>, (<bold>G</bold>) <italic>Ocln</italic>, (<bold>H</bold>) <italic>Cldn1</italic>, and (<bold>I</bold>) <italic>Muc2</italic> in colon tissue were detected by RT-qPCR. Data were shown as mean values ± SEM (n=5). Statistical significance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig6">Figure 6B–I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig6-v1.tif"/></fig><p>To further assess the impact of <italic>B. velezensis</italic> HBXN2020 on intestinal inflammatory response, the mRNA levels of inflammatory cytokines in the colonic tissues were measured. As shown in <xref ref-type="fig" rid="fig6">Figure 6B–D</xref>; <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>, the mRNA levels of <italic>Tnfa</italic> (p&lt;0.05), <italic>Il1b</italic> (p&lt;0.001), <italic>Il6</italic> (p&lt;0.001), and <italic>Il10</italic> (p&lt;0.001) in the colon tissue were significantly increased in the STm+PBS group compared to the control group. <italic>B. velezensis</italic> HBXN2020 spore treatment significantly decreased the mRNA levels of <italic>Tnfa</italic> (p&lt;0.05), <italic>Il1b</italic> (p&lt;0.001), <italic>Il6</italic> (p&lt;0.01), and increased the <italic>Il10</italic> level, compared with the STm+PBS group. In contrast, ciprofloxacin treatment failed to significantly decrease the mRNA levels of <italic>Il6</italic> in the colon of STm-infected mice (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). Similarly, ciprofloxacin treatment drastically dampened the mRNA levels of <italic>Il10</italic> in the colon of STm-infected mice (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>).</p><p>To assess the influence of <italic>B. velezensis</italic> HBXN2020 on the intestinal barrier integrity, the mRNA levels of tight junction proteins in the colonic tissues were measured. As presented in <xref ref-type="fig" rid="fig6">Figure 6</xref>, compared with control group, the mRNA levels of tight junction protein in the STm+PBS group was significantly reduced, including <italic>Tjp1</italic> (p&lt;0.05), <italic>Ocln</italic> (p&lt;0.01), <italic>Cldn1</italic>, and <italic>Muc2</italic> (p&lt;0.05) (<xref ref-type="fig" rid="fig6">Figure 6F–I</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). Moreover, the levels of tight junction protein transcription were remarkably elevated in the STm+HBXN2020, STm+CIP, and HBXN2020 group, including <italic>Tjp1</italic> (p&lt;0.001, p&lt;0.05, and p&lt;0.05, respectively), <italic>Ocln</italic> (p&lt;0.05, p&lt;0.05, and p&lt;0.01, respectively), and <italic>Cldn1</italic> (p&lt;0.001, p=0.0857, and p&lt;0.01, respectively), except for <italic>Cldn1</italic> (p=0.0857) in group STm+CIP, compared with that of the STm+PBS group (<xref ref-type="fig" rid="fig6">Figure 6F–I</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). In addition, we also detected the transcription level of <italic>Muc2</italic> in colon tissue, which mainly exists in and around goblet cells and is an important component of the mucus layer. The transcription levels of <italic>Muc2</italic> were dramatically increased in the STm+HBXN2020 group compared with the STm+PBS group (<xref ref-type="fig" rid="fig6">Figure 6I</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). Conversely, the mRNA levels of <italic>Muc2</italic> were significantly decreased in the HBXN2020 group and STm+CIP group (<xref ref-type="fig" rid="fig6">Figure 6I</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>).</p><p>Next, we further explore the impact of <italic>B. velezensis</italic> HBXN2020 on the intestinal microbiota composition of STm-treated mice by 16S rRNA gene high-throughout sequencing. As shown in <xref ref-type="fig" rid="fig7">Figure 7</xref>, alpha diversity analysis revealed that both the richness and diversity (calculated in Sobs, Chao, Shannon, and Simpson indexes) were lower in STm+PBS group than control group, HBXN2020 group, STm+HBXN2020 group, and STm+CIP group (<xref ref-type="fig" rid="fig7">Figure 7A–D</xref>, <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>). Although an increasing trend of alpha diversity was observed in STm+CIP group, but without statistical difference was achieved as compared with other groups. Principal components analysis (PCA) based on Bray-Curtis distance showed that a separation in the gut microbiota structure among control and STm+PBS group. When <italic>B. velezensis</italic> HBXN2020 spores were supplemented, the gut microbiota composition of the STm+HBXN2020 group, HBXN2020 group, and the control group were closer together (R<sup>2</sup>= 0.1616, p = 0.006, <xref ref-type="fig" rid="fig7">Figure 7E</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Oral <italic>B. velezensis</italic> HBXN2020 spores regulated the composition of intestinal microbiota.</title><p>The alpha diversity of the gut microbiota, determined by the (<bold>A</bold>) Sobs, (<bold>B</bold>) Chao, (<bold>C</bold>) Shannon, and (<bold>D</bold>) Simpson index. Data were shown as mean values ± SEM (n=5). (<bold>E</bold>) The principal components analysis (PCA) plot showed the β diversity of the gut microbiota based on Bray-Curtis distance at the operational taxonomic unit (OTU) level. Heatmap of the community composition of colonic microbiota at the phylum (top 15 phyla) (<bold>F</bold>) and genus (top 30 genera) (<bold>G</bold>) level. Relative abundance of selected taxa (<bold>H</bold>) <italic>norank_f_Muribaculaceae</italic>, (<bold>I</bold>) <italic>Lactobacillus</italic>, (<bold>J</bold>) <italic>Akkermansia</italic>, and (<bold>K</bold>) <italic>Enterococcus</italic>. Data were shown as mean values ± SEM (n=5). (<bold>L</bold>) Analysis of differences in the microbial communities by LEfSe (linear discriminant analysis [LDA] effect size) (LDA score&gt;2) among different groups. Significance was evaluated by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Raw data values for <xref ref-type="fig" rid="fig7">Figure 7A–D and H–K</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Analysis of the community compositions of colonic microbiota.</title><p>(<bold>A</bold>) Community compositions analysis at the phylum level. This bar graph shows the 15 most abundant communities. (<bold>B</bold>) Community compositions analysis at the genus level. This bar graph shows the communities of the top 30 genera.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig7-figsupp1-v1.tif"/></fig></fig-group><p>We analyzed the community composition of colonic microbiota at the phylum and genus level, and the results revealed that the composition of the gut microbiota changed markedly after STm-infected mice. At the phylum level, <italic>Bacteroidetes</italic>, <italic>Firmicutes</italic>, <italic>Verrucomicrobiota,</italic> and <italic>Proteobacteria</italic> were predominant phyla in the fecal microbiota (<xref ref-type="fig" rid="fig7">Figure 7F</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, and <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>). At the genus level, infection with STm in the STm+PBS group dramatically reduced the relative abundance of <italic>norank_f_Muribaculaceae</italic>, <italic>Lactobacillus,</italic> and <italic>Akkermansia</italic> (<xref ref-type="fig" rid="fig7">Figure 7G and H–J</xref>, <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>) and enhanced the abundance of <italic>Enterococcus</italic>, <italic>Salmonella</italic>, <italic>Bacteroides</italic>, <italic>Alloprevotella,</italic> and <italic>Escherichia-Shigella</italic> compared to the control group (<xref ref-type="fig" rid="fig7">Figure 7G and K</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, and <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>). In contrast, the STm+HBXN2020 group and HBXN2020 group significantly improved the relative abundance of <italic>norank_f_Muribaculaceae</italic> (p=0.49, p&lt;0.05) and <italic>Lactobacillus</italic> (p&lt;0.05, p&lt;0.001) compared with the STm+PBS group (<xref ref-type="fig" rid="fig7">Figure 7H and I</xref>, <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>). However, ciprofloxacin treatment significantly decreased the relative abundance of <italic>Lactobacillus</italic> (p&lt;0.05) and <italic>Akkermansia</italic> (p&lt;0.05) compared with the STm+HBXN2020 group (<xref ref-type="fig" rid="fig7">Figure 7I and J</xref>, <xref ref-type="supplementary-material" rid="fig7sdata1">Figure 7—source data 1</xref>). Differentially abundant fecal bacterial taxa in STm-treated mice in response to <italic>B. velezensis</italic> HBXN2020 and ciprofloxacin were identified by linear discriminant analysis (LDA) effect size (LEfSe) analysis (<xref ref-type="fig" rid="fig7">Figure 7L</xref>). Additionally, we found that two bacterial genera including <italic>Enterococcus</italic> and <italic>Streptococcus</italic> were enriched in the STm+PBS group, while the other three taxa were enriched including <italic>Akkermansia</italic>, <italic>Family_XIII_AD3011_group,</italic> and <italic>Corynebacterium</italic> in the STm+HBXN2020 group, <italic>Parabacteroides</italic>, <italic>NK4A214_group</italic>, <italic>Turicibacter</italic>, <italic>unclassified_o__Oscillospirales</italic>, and <italic>norank_f__Eubacterium_coprostanoligenes_group</italic> in the STm+CIP group, and <italic>norank_f_Muribaculaceae</italic>, <italic>Rikenellaceae_RC9_gut_group</italic> and <italic>Dubosiella</italic> in the HBXN2020 group (<xref ref-type="fig" rid="fig7">Figure 7L</xref>).</p></sec><sec id="s2-7"><title>Prophylactic <italic>B. velezensis</italic> HBXN2020 spores alleviated infection by <italic>S</italic>. Typhimurium</title><p>Based on the improved therapeutic efficacy of <italic>B. velezensis</italic> HBXN2020 in the treatment of STm-infected mice, we further explored its potential for disease prevention by evaluating pretreatment. Mice in the PBS+STm group, HBXN2020+STm group, and CIP+STm group were given the same amount of sterile PBS, <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin by gavage 1 week in advance. As shown in <xref ref-type="fig" rid="fig8">Figure 8</xref>, compared with the PBS+STm group, oral administration of <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin as a preventive measure remarkably alleviated infection by STm, including weight loss of mice (p&lt;0.01) (<xref ref-type="fig" rid="fig8">Figure 8B</xref>, <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>), a significant reduction in DAI (p&lt;0.001) (the comprehensive score of weight loss, stool consistency, and blood in the feces, <xref ref-type="fig" rid="fig8">Figure 8C</xref>, <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>), and the prevention of colon length shortening (<xref ref-type="fig" rid="fig8">Figure 8D and E</xref>, <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>). Meanwhile, the number of <italic>B. velezensis</italic> HBXN2020 viable bacteria in feces is also gradually decreasing with time prolonging (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig8s1sdata1">Figure 8—figure supplement 1—source data 1</xref>). Furthermore, compared with the PBS+STm group, oral administration of <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin not only reduced the number of STm in mouse feces (<xref ref-type="fig" rid="fig8">Figure 8F</xref>, <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>) but also decreased STm colonization in the ileum, cecum, and colon (<xref ref-type="fig" rid="fig8">Figure 8G and H</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>, and <xref ref-type="supplementary-material" rid="fig8s1sdata1">Figure 8—figure supplement 1—source data 1</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Prophylactic <italic>B. velezensis</italic> HBXN2020 spores attenuated the symptoms of <italic>S</italic>. Typhimurium-infected mouse.</title><p>(<bold>A</bold>) Experimental design for treatment in this study. At days 1, 3, 5, and 7, each mouse in the HBXN2020+STm group, CIP+STm group, and PBS+STm group were received 200 μL of <italic>B. velezensis</italic> HBXN2020 spores (1×10<sup>8</sup> CFU/mouse), ciprofloxacin or sterile PBS by gavage, respectively. Then, mice in PBS+STm group, HBXN2020+STm group, and CIP+STm group were orally inoculated with 200 μL (5×10<sup>7</sup> CFU/mouse) of STm on day 7, respectively. On day 12, all mice were euthanized. (<bold>B</bold>) Daily body weight changes and (<bold>C</bold>) daily disease activity index (DAI) scores of mice with different groups following STm treatment. Data were shown as mean values ± SEM (n=6). Statistical significance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001). (<bold>D</bold>) Colonic tissue images. (<bold>E</bold>) The length of the colon from per group (n=6). (<bold>F</bold>) Bacterial count of STm in mouse feces. Fecal samples were collected every day after STm infection and resuspended in sterile PBS (0.1 g of fecal resuspended in 1 mL of sterile PBS) (n=6). One hundred microliters of each sample performed a serial of 10-fold dilutions and spread on selective agar plates (50 µg/mL kanamycin) and incubated at 37°C for 12 hr before bacterial counting. The bacterial loads of STm in (<bold>G</bold>) cecum and (<bold>H</bold>) colon (n=6). The cecum and colon were harvested and then homogenized. Statistical significance was evaluated using Student’s t-test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Raw numerical data for <xref ref-type="fig" rid="fig8">Figure 8B, C, and E–H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig8-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig8sdata2"><label>Figure 8—source data 2.</label><caption><title>PDF file containing original colonic tissue image for <xref ref-type="fig" rid="fig8">Figure 8D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig8-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata3"><label>Figure 8—source data 3.</label><caption><title>Original files for colonic tissue image displayed in <xref ref-type="fig" rid="fig8">Figure 8D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-93423-fig8-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>The effect of prophylactic <italic>B. velezensis</italic> HBXN2020 on the bacterial load in feces or ileum of mice and the histological score of the colons.</title><p>(<bold>A</bold>) The bacterial load of <italic>B. velezensis</italic> HBXN2020 in mouse feces. The quantity of <italic>B. velezensis</italic> HBXN2020 was identified by combining bacterial count and PCR (n=5). Data were shown as mean values ± SEM. (<bold>B</bold>) The bacterial loads of <italic>S</italic>. Typhimurium ATCC14028 in ileum. The ileum was harvested and then homogenized. One hundred microliters of each sample performed a serial of 10-fold dilutions and spread on selective agar plates and incubated at 37°C for 12 hr before bacterial counting. Data were shown as mean values ± SEM (n=6).Statistical significance was evaluated using Student’s t-test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001). (<bold>C</bold>) Histological scores of colons (n=3). (<bold>D</bold>) <italic>B. velezensis</italic> HBXN2020 single colony PCR identification results. Statistical significance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig8s1sdata1"><label>Figure 8—figure supplement 1—source data 1.</label><caption><title>Raw numerical data for <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig8-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig8-figsupp1-v1.tif"/></fig></fig-group><p>Histological analysis further revealed that prophylactic <italic>B. velezensis</italic> HBXN2020 spore suppressed STm-induced loss of the intestinal epithelium, inflammatory cell infiltration, and colonic mucosa damage (<xref ref-type="fig" rid="fig9">Figure 9A</xref>), while prophylactic ciprofloxacin failed to inhibit the loss of colonic epithelial cells. We next measured the mRNA levels of inflammatory cytokines and tight junction proteins in colon tissue in the prophylactic animal experiment. As with the treatment test, prophylactic <italic>B. velezensis</italic> HBXN2020 spores largely attenuated the mRNA levels of <italic>Tnfa</italic> (p&lt;0.001), <italic>Il1b</italic> (p&lt;0.001), and <italic>Il6</italic> (p&lt;0.001), and significantly increased levels of <italic>Il10</italic> (p&lt;0.05), in the colon tissue of mice compared with the PBS+STm group (<xref ref-type="fig" rid="fig9">Figure 9B–E</xref>, <xref ref-type="supplementary-material" rid="fig9sdata1">Figure 9—source data 1</xref>). Similarly, prophylactic ciprofloxacin significantly reduced the mRNA levels of <italic>Tnfa</italic> (p&lt;0.01) and <italic>Il1b</italic> (p&lt;0.001), and drastically elevated levels of <italic>Il10</italic> (p&lt;0.001) in the colon tissue of mice compared with the PBS+STm group (<xref ref-type="fig" rid="fig9">Figure 9B, C, and E</xref>, <xref ref-type="supplementary-material" rid="fig9sdata1">Figure 9—source data 1</xref>). Also, prophylactic <italic>B. velezensis</italic> HBXN2020 spores significantly increased the transcription levels of <italic>Tjp1</italic> (p&lt;0.001), <italic>Ocln</italic> (p&lt;0.001), <italic>Cldn1</italic> (p&lt;0.05), and <italic>Muc2</italic> (p&lt;0.001) compared with that of the PBS+STm group (<xref ref-type="fig" rid="fig9">Figure 9F–I</xref>, <xref ref-type="supplementary-material" rid="fig9sdata1">Figure 9—source data 1</xref>). Notably, the mRNA levels of <italic>Tjp1</italic> (p&lt;0.001), <italic>Ocln</italic> (p&lt;0.05), and <italic>Muc2</italic> (p&lt;0.05) in the CIP+STm group were significantly lower than those in the HBXN2020+STm group. Overall, these results suggested that prophylactic <italic>B. velezensis</italic> HBXN2020 spores was capable of alleviating STm-induced colonic injury and inflammation.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Prophylactic <italic>B. velezensis</italic> HBXN2020 spores attenuated colonic damage and inflammatory reaction.</title><p>(<bold>A</bold>) Hematoxylin and eosin (H&amp;E) stained colon tissue sections. Scale bar: 50 μm. The mRNA levels of (<bold>B</bold>) <italic>Tnfa</italic>, (<bold>C</bold>) <italic>Il1b</italic>, (<bold>D</bold>) <italic>Il6</italic>, and (<bold>E</bold>) <italic>Il10</italic> were detected by RT-qPCR. Data were shown as mean values ± SEM (n=5). The mRNA levels of (<bold>F</bold>) <italic>Tjp1</italic>, (<bold>G</bold>) <italic>Ocln</italic>, (<bold>H</bold>) <italic>Cldn1</italic>, and (<bold>I</bold>) <italic>Muc2</italic> in colon tissue were detected by RT-qPCR. Data were shown as mean values ± SEM (n=5). Statistical significance was evaluated using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Raw numerical data for <xref ref-type="fig" rid="fig9">Figure 9B–I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig9-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig9-v1.tif"/></fig><p>Next, we examined the impact of prophylactic <italic>B. velezensis</italic> HBXN2020 on the intestinal microbiota composition of STm-treated mice. Sobs, Chao, and Shannon index were significantly increased in the HBXN2020, PBS+STm group, HBXN2020+STm group, and CIP+STm group compared with the control group (<xref ref-type="fig" rid="fig10">Figure 10A–C</xref>, <xref ref-type="supplementary-material" rid="fig10sdata1">Figure 10—source data 1</xref>), while the Simpson index (not statistically different) significantly decreased (<xref ref-type="fig" rid="fig10">Figure 10D</xref>, <xref ref-type="supplementary-material" rid="fig10sdata1">Figure 10—source data 1</xref>). PCA showed significant separation between control and PBS+STm groups (R<sup>2</sup>=0.3186, p=0.014, <xref ref-type="fig" rid="fig10">Figure 10E</xref>). When <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin were supplemented, the community clustering was significantly similar to that of the control group rather than the PBS+STm group (<xref ref-type="fig" rid="fig10">Figure 10E</xref>). Meanwhile, the overall fecal bacterial composition of mice at the phylum and genus level in all groups was similar to that of the treatment experiment. The fecal microbiota was dominated by phyla <italic>Firmicutes</italic>, <italic>Bacteroidetes</italic>, <italic>Verrucomicrobiota</italic>, <italic>Patescibacteria</italic>, and <italic>Actinobacteria</italic> in all five groups (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1</xref>). At the genus level, PBS+STm group exhibited lower relative abundances of <italic>Lactobacillus</italic> and <italic>Akkermansia</italic> (<xref ref-type="fig" rid="fig10">Figure 10G–I</xref>, <xref ref-type="supplementary-material" rid="fig10sdata1">Figure 10—source data 1</xref>), and higher relative abundances of <italic>Alistipes</italic>, <italic>Bacteroides</italic>, <italic>Escherichia-Shigella</italic>, <italic>Enterococcus</italic>, and <italic>Alloprevotella</italic>, compared with the control (<xref ref-type="fig" rid="fig10">Figure 10G and J–M</xref>, <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1</xref>, and <xref ref-type="supplementary-material" rid="fig10sdata1">Figure 10—source data 1</xref>). Moreover, compared with the PBS+STm group, following supplementation with <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin, <italic>Lactobacillus</italic> significantly increased, and the gut microbiota was restored to a composition similar to the control group. It was noteworthy that six bacterial genera including <italic>Alistipes</italic>, <italic>Odoribacter</italic>, and <italic>norank_f__Oscillospiraceae</italic> were enriched in PBS+STm group, while other three taxa (e.g. <italic>Lactobacillus</italic> and <italic>Akkermansia</italic>) were enriched in the control group (<xref ref-type="fig" rid="fig10">Figure 10N</xref>). Moreover, we found that <italic>Candidatus_Arthromitus</italic> was enriched in the HBXN2020+STm group, <italic>Dubosiella</italic> was enriched in the CIP+STm group, and <italic>Faecalibaculum</italic>, <italic>Rikenellaceae_RC9_gut_group</italic>, and <italic>unclassified_f__Lactobacillaceae</italic> were enriched in the HBXN2020 group (<xref ref-type="fig" rid="fig10">Figure 10N</xref>). Above all, these results indicated that prophylactic <italic>B. velezensis</italic> HBXN2020 spores regulated the gut microbiota composition, leading to the potential to attenuate the STm-induced dysbiosis.</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Prophylactic <italic>B. velezensis</italic> HBXN2020 spores regulated the composition of gut microbiota.</title><p>(<bold>A–D</bold>) Alpha diversity of the intestinal microbiota. Data were shown as mean values ± SEM (n=5). (<bold>E</bold>) The principal components analysis (PCA) plot showed the β diversity among different microbial community groups based on Bray-Curtis distance at the operational taxonomic unit (OTU) level. Heatmap of the community composition of colonic microbiota at the phylum (top 15 phyla) (<bold>F</bold>) and genus (top 30 genera) (<bold>G</bold>) level. Relative abundance of selected taxa (<bold>H</bold>) <italic>Lactobacillus</italic>, (<bold>I</bold>) <italic>Akkermansia</italic>, (<bold>J</bold>) <italic>Alistipes</italic>, (<bold>K</bold>) <italic>Bacteroides</italic>, (<bold>L</bold>) <italic>Escherichia-Shigella</italic>, and (<bold>M</bold>) <italic>Enterococcus</italic>. Data were shown as mean values ± SEM (n=5). (<bold>N</bold>) Analysis of differences in the microbial taxa by LEfSe (linear discriminant analysis [LDA] effect size) (LDA score&gt;2) in different groups. Significance was evaluated by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (*, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001).</p><p><supplementary-material id="fig10sdata1"><label>Figure 10—source data 1.</label><caption><title>Raw numerical data for <xref ref-type="fig" rid="fig10">Figure 10A–D and H–M</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-93423-fig10-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig10-v1.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>Analysis of the community compositions of colonic microbiota.</title><p>(<bold>A</bold>) Community compositions analysis at the phylum level. This bar graph shows the 15 most abundant communities. (<bold>B</bold>) Community compositions analysis at the genus level. This bar graph shows the communities of the top 30 genera.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-93423-fig10-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p><italic>S. Typhimurium</italic> is an important intestinal pathogen that can cause invasive intestinal diseases such as bacterial colitis (<xref ref-type="bibr" rid="bib21">Herp et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Schultz et al., 2017</xref>). Antibiotics are frequently used to treat colitis caused by bacteria; nevertheless, in recent years, their abuse has greatly increased bacterial resistance, leading to serious environmental pollution. A recent study showed that antibiotic resistance genes in probiotics could be transmitted to the intestinal microbiota, which may threaten human health (<xref ref-type="bibr" rid="bib10">Crits-Christoph et al., 2022</xref>). It is crucial to consider the source of probiotics. Strong environmental adaptability and disease resistance make black pigs an outstanding household breed in China (<xref ref-type="bibr" rid="bib60">Yang et al., 2022</xref>). In this study, <italic>B. velezensis</italic> HBXN2020 was isolated from the free-range feces of black piglets in a mountain village in Xianning City (Hubei, China) and exhibited excellent antibacterial activity. Otherwise, in vitro tolerance assays showed that <italic>B. velezensis</italic> HBXN2020 spores have good tolerance to high temperature, strong acids, bile salts, as well as simulated gastric and intestinal fluid, which was similar to previous research results (<xref ref-type="bibr" rid="bib13">Du et al., 2022</xref>). Furthermore, studies for antibiotic susceptibility revealed that <italic>B. velezensis</italic> HBXN2020 is not resistant to antibiotics.</p><p>Probiotics are distinct from food or medications in that they can cause toxins or infections in the body when ingested, and they are living when swallowed (<xref ref-type="bibr" rid="bib42">Sanders et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Snydman, 2008</xref>). Therefore, assessing the biosafety of probiotics is crucial. In this study, the safety of <italic>B. velezensis</italic> HBXN2020 was evaluated by measuring the body weight, intestinal barrier proteins, and inflammatory cytokines of the experimented mice, as well as conducting routine blood and biochemical tests. The results showed that the expression levels of <italic>Tjp1</italic> and <italic>Ocln</italic> in the colon of mice increased after treatment with different doses of <italic>B. velezensis</italic> HBXN2020 spores. It has been reported that <italic>Tjp1</italic>, <italic>Ocln,</italic> and <italic>Cldn1</italic> are the three most important tight junction proteins in intercellular connections, which play a crucial role in maintaining the intestinal epithelial barrier (<xref ref-type="bibr" rid="bib2">Bazzoni et al., 2000</xref>; <xref ref-type="bibr" rid="bib66">Zihni et al., 2016</xref>). Thus, it is possible to improve intestinal barrier function by upregulating <italic>Tjp1</italic> and <italic>Ocln</italic> expression levels.</p><p>Important aminotransferases in animals, AST and ALT, are regarded as critical metrics for assessing liver function damage (<xref ref-type="bibr" rid="bib18">Gou et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Ozer et al., 2008</xref>). Under normal circumstances, the levels of ALT and AST are in dynamic balance without notable changes. However, when the liver is damaged or becomes dysfunctional, the levels of aminotransferases (ALT and AST) increase significantly (<xref ref-type="bibr" rid="bib51">Tang et al., 2012</xref>). Previous studies have shown that CCL4-induced liver injury strongly increases plasma ALT/AST levels (<xref ref-type="bibr" rid="bib47">Singhal et al., 2018</xref>). Zhang et al. reported that the addition of <italic>Bacillus subtilis</italic> to chicken diets significantly decreased the serum levels of ALT and AST (<xref ref-type="bibr" rid="bib62">Zhang et al., 2017</xref>). In this present study, the levels of ALT and AST in the probiotic-treated group were slightly lower than those in the control group, indicating that <italic>B. velezensis</italic> HBXN2020 had no negative effect on liver health in mice. The <italic>B. velezensis</italic> HBXN2020 treatment group’s blood indices were also found to be comparable to those of the control group, falling within the normal reference range, according to regular blood testing.</p><p>Mice were fed with <italic>B. velezensis</italic> HBXN2020 spores orally after being challenged with <italic>S</italic>. Typhimurium ATCC14028 in order to assess the spores’ potential to alleviate infection caused by <italic>S</italic>. Typhimurium. Our experimental results demonstrated that oral treatment with <italic>B. velezensis</italic> HBXN2020 spores could alleviate infection by <italic>S</italic>. Typhimurium, as evidenced by decreased weight loss, DAI, and histological damage, which is similar to prior studies (<xref ref-type="bibr" rid="bib5">Cao et al., 2019</xref>; <xref ref-type="bibr" rid="bib58">Wu et al., 2022</xref>). Previous research showed that macrophages are the first line of host defense against bacterial infection. They release proinflammatory cytokines, which are critical in initiating adaptive immune responses (<xref ref-type="bibr" rid="bib7">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Dinarello, 2000</xref>). Nevertheless, proinflammatory cytokines have immunological properties that can be beneficial for the host to resist the invasion of bacteria and other microbes in the surrounding environment (<xref ref-type="bibr" rid="bib29">Liu et al., 2021</xref>). For instance, pretreatment with recombinant murine <italic>Tnfa</italic> was shown to protect mice against lethal bacterial (<italic>E. coli</italic>) infection (<xref ref-type="bibr" rid="bib11">Cross et al., 1989</xref>). PJ-34 exerted protective effects on intestinal epithelial cells against invasive <italic>Salmonella</italic> infection by upregulating <italic>Il6</italic> expression through the ERK and NF-κB signaling pathways (<xref ref-type="bibr" rid="bib22">Huang, 2009</xref>).</p><p>On the other hand, some research has demonstrated that over-activation of immune cells can result in tissue damage, organ failure, systemic or persistent inflammation, and autoimmune diseases (<xref ref-type="bibr" rid="bib23">Karki et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Kotas and Medzhitov, 2015</xref>). <italic>Il10</italic> is a recognized anti-inflammatory mediator that plays a crucial role in maintaining intestinal microbe-immune homeostasis, regulating the release of inflammatory mediators, and inhibiting proinflammatory responses of innate and adaptive immunity (<xref ref-type="bibr" rid="bib31">Maloy and Powrie, 2011</xref>; <xref ref-type="bibr" rid="bib36">Ouyang et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Saraiva et al., 2020</xref>). For instance, previous studies have shown that <italic>Clostridium butyrate</italic> can induce the production of <italic>Il10</italic> in the intestine, thereby alleviating experimental colitis in mice (<xref ref-type="bibr" rid="bib20">Hayashi et al., 2013</xref>). Similar results were observed in our study, where oral administration of <italic>B. velezensis</italic> HBXN2020 spores reduced the expression levels of <italic>Tnfa</italic>, <italic>Il1b</italic>, and <italic>Il6</italic> while increasing the levels of <italic>Il10</italic> in the colon of mice. Additionally, as demonstrated by the decreased histological damage and increased expression levels of intestinal barrier proteins, oral treatment of <italic>B. velezensis</italic> HBXN2020 spores reduced the functional damage of the intestinal barrier induced by S. Typhimurium infection.</p><p>Besides host itself, environmental factors such as diet and gut microbiota have been associated with the development of STm-infected. Gut microbiota constitutes a critical bridge between environmental factors and host health, where the beneficial bacteria such as <italic>Lactobacillus</italic> in the microbiota may exert repair and anti-inflammatory function (<xref ref-type="bibr" rid="bib28">Li et al., 2022</xref>; <xref ref-type="bibr" rid="bib30">Liu et al., 2022</xref>). Moreover, supplementation of probiotics has been shown to modulate intestinal microbiota and reduce the risk of STm-infected (<xref ref-type="bibr" rid="bib3">Buddhasiri et al., 2021</xref>; <xref ref-type="bibr" rid="bib64">Zhang et al., 2022</xref>). This is consistent with our research results between the <italic>B. velezensis</italic> HBXN2020 treatment group and STm-infected mice. Here, we found that oral <italic>B. velezensis</italic> HBXN2020 spores raised the colonic microbiota’s alpha diversity and modulated the composition of the intestinal microbiota, namely, enriching the relative abundance of <italic>Lactobacillus</italic> (known for enhancing the epithelial barrier by increasing mucus secretion and upregulating the expression of tight junction proteins such as <italic>Cldn1</italic>, <italic>Ocln</italic>, and <italic>Tjp1</italic>) (<xref ref-type="bibr" rid="bib25">Kaur et al., 2021</xref>) and <italic>Akkermansia</italic> (known for modulating intestinal immune response by producing short-chain fatty acids and reducing the secretion of proinflammatory cytokines) (<xref ref-type="bibr" rid="bib4">Cani et al., 2022</xref>), reducing the relative abundance of <italic>Enterococcus</italic>, <italic>Salmonella,</italic> and <italic>Bacteroides</italic> (harmful to intestinal homeostasis) (<xref ref-type="bibr" rid="bib56">Wang et al., 2023</xref>). Notably, we also found that the relative abundance of <italic>Lactobacillus</italic> and <italic>Akkermansia</italic> in the ciprofloxacin treatment group was significantly lower than that in the <italic>B. velezensis</italic> HBXN2020 spores treatment group, indicating that excessive use of antibiotics may interfere with the recovery of beneficial bacteria in the gut. Collectively, infection with <italic>S</italic>. Typhimurium disrupts gut microbiota and the gut barrier, leading to intestinal inflammation, while oral <italic>B. velezensis</italic> HBXN2020 spores protects the colon and reduce infection by increasing the abundance of beneficial bacteria and barrier integrity and decreasing inflammation.</p><p>We further assessed pretreatment in order to learn more about the potential of <italic>B. velezensis</italic> HBXN2020 spores for disease prevention, given the increased efficacy of treating infection caused by <italic>S</italic>. Typhimurium. Similar to the therapeutic effect of oral <italic>B. velezensis</italic> HBXN2020, prophylactic <italic>B. velezensis</italic> HBXN2020 spores effectively alleviated the symptoms of STm-infected mice, namely, reduced the mRNA levels of proinflammatory cytokines and increased the anti-inflammatory cytokine level in the colon of STm-infected mice. Prophylactic <italic>B. velezensis</italic> HBXN2020 spores also increased the mRNA levels of gut barrier proteins in the colon of STm-infected mice. Furthermore, the microbiota composition was also dramatically modulated by prophylactic <italic>B. velezensis</italic> HBXN2020 spores in both healthy mice and STm-infected mice. Also, the community richness revealed by the alpha diversity index were not significantly impacted in STm-infected mice by prophylactic <italic>B. velezensis</italic> HBXN2020 spores. Interestingly, we found that prophylactic <italic>B. velezensis</italic> HBXN2020 spores significantly increased the community diversity in healthy mice, suggesting the potentially beneficial effects of <italic>B. velezensis</italic> HBXN2020 in gut microenvironment for animals in the future. Moreover, prophylactic <italic>B. velezensis</italic> HBXN2020 spores significantly boosted SCFA-producing bacteria including <italic>Lactobacillus</italic> and <italic>Akkermansia</italic>, which was consistent with the effects of therapeutic oral <italic>B. velezensis</italic> HBXN2020 spores. Meanwhile, harmful bacteria such as <italic>Alistipes</italic>, <italic>Bacteroides</italic>, <italic>Escherichia-Shigella</italic>, and <italic>Enterococcus</italic> were significantly enriched in STm-infected mice, reminding us that increased harmful bacteria might play a major role in promoting the development of STm-infected. In summary, our results demonstrated that <italic>B. velezensis</italic> HBXN2020-mediated microbial communities, especially <italic>Lactobacillus</italic> and <italic>Akkermansia,</italic> might play a crucial role in alleviating the development of STm-infected.</p><sec id="s3-1"><title>Conclusion</title><p>In conclusion, <italic>S</italic>. Typhimurium ATCC14028 infection can result in gut barrier disruption and intestinal inflammation and intestinal microbiota dysbiosis. Supplementing <italic>B. velezensis</italic> HBXN2020 spores can improve intestinal microbiota stability and gut barrier integrity and reduce inflammation to help prevent or treat infection by <italic>S</italic>. Typhimurium. Thus, our results indicate that supplementing <italic>B. velezensis</italic> HBXN2020 may represent a novel option for preventing <italic>Salmonella</italic> infections.</p><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Bacillus velezensis</italic>)</td><td align="left" valign="bottom">HBXN2020</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">NCBI GenBank accession No: CP119399.1</td><td align="left" valign="bottom">This strain is used in the entire text</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Salmonella</italic> Typhimurium)</td><td align="left" valign="bottom">STm</td><td align="left" valign="bottom">ATCC</td><td align="char" char="." valign="bottom">14028</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="char" char="." valign="bottom">25922</td><td align="left" valign="bottom">ATCC</td><td align="char" char="." valign="bottom">25922</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>E. coli</italic>)</td><td align="char" char="." valign="bottom">35150</td><td align="left" valign="bottom">ATCC</td><td align="char" char="." valign="bottom">35150</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>E. coli</italic>)</td><td align="left" valign="bottom">EC024</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>S</italic>. Typhimurium)</td><td align="left" valign="bottom">SL1344</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib17">Gao et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>S</italic>. Enteritidis)</td><td align="left" valign="bottom">SE006</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib17">Gao et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Staphylococcus aureus</italic>)</td><td align="char" char="." valign="bottom">29213</td><td align="left" valign="bottom">ATCC</td><td align="char" char="." valign="bottom">29213</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>S. aureus</italic>)</td><td align="char" char="." valign="bottom">43300</td><td align="left" valign="bottom">ATCC</td><td align="char" char="." valign="bottom">43300</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>S. aureus</italic>)</td><td align="left" valign="bottom">S21</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Clostridium perfringens</italic>)</td><td align="char" char="." valign="bottom">2030</td><td align="left" valign="bottom">CVCC</td><td align="char" char="." valign="bottom">2030</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>C. perfringens</italic>)</td><td align="left" valign="bottom">CP023</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>C. perfringens</italic>)</td><td align="left" valign="bottom">CP002</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Streptococcus suis</italic>)</td><td align="left" valign="bottom">SC19</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib14">Duan et al., 2023</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>S. suis</italic>)</td><td align="left" valign="bottom">SS006</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Pasteurella multocida</italic>)</td><td align="left" valign="bottom">PM002</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>P. multocida</italic>)</td><td align="left" valign="bottom">PM008</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Actinobacillus pleuropneumoniae</italic>)</td><td align="left" valign="bottom">APP015</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>A. pleuropneumoniae</italic>)</td><td align="left" valign="bottom">APP017</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">This strain is used in <xref ref-type="fig" rid="fig2">Figure 2B</xref></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tnfa</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CCACGCTCTTCTGTCTACTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tnfa</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ACTTGGTGGTTTGCTACGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il1b</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">ACCTGTGTCTTTCCCGTGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il1b</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TCATCTCGGAGCCTGTAGTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il6</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GAGCCCACCAAGAACGATA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il6</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TTGTCACCAGCATCAGTCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il10</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TGGACAACATACTGCTAACCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Il10</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGGCATCACTTCTACCAGGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tjp1</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CTGGTGAAGTCTCGGAAAAATG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Tjp1</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CATCTCTTGCTGCCAAACTATC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ocln</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGGATGCCAATTACCATCAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Ocln</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GGGTTCACTCCCATTATGTACA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cldn1</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">AGATACAGTGCAAAGTCTTCGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Cldn1</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGGATGCCAATTACCATCAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Muc2</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CGAGCACATCACCTACCACATCATC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Muc2</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">TCCAGAATCCAGCCAGCCAGTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">β-actin-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">GACCTCTATGCCAACACAGT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">β-actin-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom"><named-content content-type="sequence">CACCAATCCACACAGAGTAC</named-content></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">HiScript III RT SuperMix</td><td align="left" valign="bottom">Vazyme Biotechnology Co., Ltd</td><td align="left" valign="bottom">#R323-01</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">qPCR SYBR Green Master Mix</td><td align="left" valign="bottom">Yeasen Biotechnology Co., Ltd</td><td align="left" valign="bottom">#11203ES08</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">E.Z-N.A Stool DNA Kit</td><td align="left" valign="bottom">Omega</td><td align="left" valign="bottom">#D4015-01</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Kanamycin</td><td align="left" valign="bottom">Solarbio</td><td align="left" valign="bottom">#K8020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ciprofloxacin</td><td align="left" valign="bottom">Solarbio</td><td align="left" valign="bottom">#C9710</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ampicillin</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C002</td><td align="left" valign="bottom">10 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Meropenem</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C102</td><td align="left" valign="bottom">10 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Piperacillin</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C005</td><td align="left" valign="bottom">10 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gentamycin</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C017</td><td align="left" valign="bottom">10 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tetracycline</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C021</td><td align="left" valign="bottom">30 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Doxycycline</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C032</td><td align="left" valign="bottom">30 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Minocycline</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C046</td><td align="left" valign="bottom">30 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Erythromycin</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C023</td><td align="left" valign="bottom">15 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Enrofloxacin</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT0639B</td><td align="left" valign="bottom">5 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ofloxacin</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C044</td><td align="left" valign="bottom">5 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sulfamethoxazole</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT0051B</td><td align="left" valign="bottom">25 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trimethoprim-sulfamethoxazole</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C027</td><td align="left" valign="bottom">23.75 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Polymyxin B</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT0044B</td><td align="char" char="." valign="bottom">300 U/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Teicoplanin</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT0647B</td><td align="left" valign="bottom">30 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trimethoprim</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT0076B</td><td align="left" valign="bottom">5 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Florfenicol</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT1754B</td><td align="left" valign="bottom">30 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Spectinomycin</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT0046B</td><td align="left" valign="bottom">10 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nitrofurantoin</td><td align="left" valign="bottom">Shunyou Shanghai Biotechnology Co., Ltd</td><td align="left" valign="bottom">#CT0036B</td><td align="left" valign="bottom">300 µg/tablet</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rifampicin</td><td align="left" valign="bottom">Hangzhou Binhe Microorganism Reagent Co., Ltd</td><td align="left" valign="bottom">#C013</td><td align="left" valign="bottom">5 µg/tablet</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Sample collection and strain isolation</title><p>Fresh fecal samples were collected from the farms of various locations in southern China including Hubei, Anhui, Hunan, Jiangxi, Guizhou, and Guangxi. All samples were placed in sterile plastic bags, sealed and placed on ice, and immediately transported to the laboratory. <italic>Bacillus</italic> was isolated following a previously described method with slight modification (<xref ref-type="bibr" rid="bib53">Unban et al., 2020</xref>). The obtained strains were kept in Luria-Bertani (LB) media containing 25% (vol/vol) glycerol and stored at −80°C, and prepared in LB medium or LB agar medium before use.</p></sec><sec id="s4-2"><title>Antibacterial activity of <italic>Bacillus</italic></title><p>The antibacterial activity of <italic>Bacillus</italic> isolates was evaluated by using the spot-on-plate method on LB agar plates supplemented with indicator bacteria (<italic>Salmonella</italic>, <italic>E. coli</italic>, <italic>S. aureus</italic>). Briefly, an overnight culture of indicator bacteria was dipped by sterile cotton swabs and spread on LB agar plates. <italic>Bacillus</italic> solution was spotted onto the double-layer agar plates and incubated at 37°C for 12 hr to measure the inhibition zone. A transparent zone of at least 1 mm around the spot was considered positive.</p><p>The antibacterial spectrum of <italic>Bacillus</italic> isolates was compared through the agar diffusion test, based on the results of the spot-on-plate test. In brief, an overnight culture of indicator strains was mixed with 10 mL of TSB soft agar (TSB broth containing 0.7% [wt/vol] agar) and poured into a sterile plate covered with LB agar and Oxford cups, 8 mm diameter wells were prepared in the TSB agar after removing the cups. The wells were filled with 100 μL of <italic>Bacillus</italic> solution. The plates were incubated at 37°C for 14 hr, and the inhibition zone was measured.</p><p>The indicator strains used in this study are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>, and all the primers used in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. <italic>C. perfringens</italic> were cultured in a fluid thioglycollate medium (FTG) (Hopebio, Qingdao, China) at 45°C. <italic>S. suis</italic> and <italic>P. multocida</italic> were cultured in TSB medium supplemented with 5% (vol/vol) sheep serum (Solarbio, Beijing, China) at 37°C, and <italic>A. pleuropneumoniae</italic> were cultured in TSB supplemented with 5% (vol/vol) sheep serum and 5 mM nicotinamide adenine dinucleotide at 37°C, while the other bacterial strains were cultured in LB medium (Solarbio, Beijing, China) at 37°C. In addition, the Difco sporulation medium was used for inducing the sporulation of <italic>Bacillus</italic> via the nutrient depletion method (<xref ref-type="bibr" rid="bib52">Tang et al., 2017</xref>).</p></sec><sec id="s4-3"><title>Growth curves of HBXN2020</title><p>The growth curve of HBXN2020 was recorded in flat-bottomed 100-well microtiter plates via detecting optical density at 600 nm (OD<sub>600</sub>) at 1 hr intervals using the automatic growth curve analyzer (Bioscreen, Helsinki, Finland).</p></sec><sec id="s4-4"><title>In vitro resistance assay of HBXN2020</title><p>HBXN2020 spores (100 μL) or vegetative cells (100 μL) were separately resuspended in 900 μL of LB medium supplemented with different pH values (2, 3, 4, 5, or 6), bile salts (0.85% NaCl, 0.3%), simulated gastric fluid (SGF, HCl, pH 1.2) containing 10 g/L of pepsin in 0.85% NaCl solution, or simulated intestinal fluid (SIF, NaOH, pH 6.8) containing 10 g/L of trypsin in 0.05 M KH<sub>2</sub>PO<sub>4</sub> solution, and incubated at 37°C. A normal LB medium (pH 7.0) was used as the control. At predetermined time points, 100 μL was taken from each sample, serially diluted 10-fold with sterile PBS (pH 7.2), and then spread onto LB agar plates. The plates were incubated overnight in a constant temperature incubator at 37°C, and the bacterial colonies were counted. The survival rate was calculated using the following formula: Survival rate = (number of bacteria in the treatment group/number of bacteria in the control group)×100%.</p><p>One milliliter of HBXN2020 spores or vegetative cells were separately placed in water baths at different temperatures (37°C, 45°C, 55°C, 65°C, 75°C, 85°C, or 95°C) for 20 min, with a 37°C water bath used as the control. The survival rate was calculated as described above.</p></sec><sec id="s4-5"><title>Antibiotic susceptibility assays</title><p>Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method in accordance with the Clinical Laboratory Standards Institute (CLSI) guidelines (<xref ref-type="bibr" rid="bib8">CLSI, 2018</xref>.). The antimicrobial agents tested were: Ampicillin, Meropenem, Piperacillin, Gentamycin, Tetracycline, Doxycycline, Minocycline, Erythromycin, Enrofloxacin, Ofloxacin, Sulfamethoxazole, Trimethoprim-sulfamethoxazole, Polymyxin B, Teicoplanin, Trimethoprim, Florfenicol, Spectinomycin, Nitrofurantoin, and Rifampicin. The diameter of the inhibition zone was measured using a vernier caliper.</p></sec><sec id="s4-6"><title>Antimicrobial assays</title><p>The in vitro antagonistic activity of HBXN2020-CFS was tested using the agar well-diffusion method against 18 indicator strains (pathogens), which included 7 standard strains (<italic>E. coli</italic> ATCC 25922, <italic>E. coli</italic> ATCC 35150, <italic>S</italic>. Typhimurium ATCC 14028 (STm), <italic>S</italic>. Typhimurium SL1344, <italic>S. aureus</italic> ATCC 29213, <italic>S. aureus</italic> ATCC 43300, and <italic>C. perfringens</italic> CVCC 2030) and 11 clinical isolates (<italic>E. coli</italic> EC024, <italic>S</italic>. Enteritidis SE006, <italic>S. aureus</italic> S21, <italic>C. perfringens</italic> CP023, <italic>C. perfringens</italic> CP002, <italic>S. suis</italic> SC19, <italic>S. suis</italic> SS006, <italic>P. multocida</italic> PM002, <italic>P. multocida</italic> PM008, <italic>A. pleuropneumoniae</italic> APP015, and <italic>A. pleuropneumoniae</italic> APP017). All plates were cultured at 37°C for 16 hr before observing the inhibition zone, and the diameter of the inhibition zone was measured using a vernier caliper. The presence of a clear zone indicated antagonistic activity.</p></sec><sec id="s4-7"><title>In vitro bacterial competition</title><p>To investigate whether HBXN2020 directly inhibited the growth of STm, we performed spot-on lawn and agar well-diffusion assays, as well as co-culture assays in liquid culture medium. In the spot-on lawn antimicrobial assays, we prepared double layers of agar by first pouring LB agar into the plate as the bottom layer. The top layer consisted of 10 mL TSB broth containing 0.7% agar with STm overnight culture. Then, 10 μL of HBXN2020 overnight culture and cell-free supernatant (CFS) were respectively spotted onto TSB agar and incubated at 37°C for 12 hr to measure the inhibition zone. A transparent zone of at least 1 mm around the spot was considered positive.</p><p>The antagonistic effect of HBXN2020-CFS against STm was determined using the agar well-diffusion assays. To collect HBXN2020-CFS, the culture was centrifuged at 9000×<italic>g</italic> for 15 min at 4°C, and the supernatant was filtered through a 0.22 μm membrane filter (Millipore, USA). The STm lawn medium was prepared by mixing 10 mL of TSB broth containing 0.7% agar with STm overnight culture and then poured into a sterile plate covered with LB agar and Oxford cups, 8 mm diameter wells were prepared in the TSB agar after removing the cups. The wells were filled with 100 μL of HBXN2020-CFS, LB medium, or ampicillin (100 µg/mL). The plates were incubated at 37°C for 14 hr, and the inhibition zone was measured.</p><p>The co-culture assay was conducted by incubating HBXN2020 and <italic>S</italic>. Typhimurium ATCC14028 (carry pET28a (+), kanamycin resistance) (<xref ref-type="bibr" rid="bib5">Cao et al., 2019</xref>) separately overnight at 37°C and diluting them to 10<sup>4</sup> CFU/mL. Then, the two strains were mixed at different ratios (1:1, 1:10, 1:50, or 1:100) and co-cultured at 37°C with shaking (180 rpm). At predetermined time points, serial 10-fold dilutions were prepared for all samples and spread onto selective (kanamycin 50 µg/mL) LB agar plates and cultured at 37°C for 12 hr before bacterial counting. Viable colony counts ranged from 30 to 300 per plate.</p></sec><sec id="s4-8"><title>Genome sequencing, annotation, and analysis</title><p>The complete genome of strain was sequenced using the Illumina HiSeq PE and PacBio RSII (SMRT) platforms (Shanghai Majorbio Bio-Pharm Technology Co., Ltd.). Briefly, the short reads from the Illumina HiSeq PE were assembled into contigs using SPAdenovo (<ext-link ext-link-type="uri" xlink:href="http://soap.genomics.org.cn/">http://soap.genomics.org.cn/</ext-link>). The long reads from the PacBio RSII and the Illumina contigs were then aligned using the miniasm and Racon tools in Unicycler (version 0.4.8, <ext-link ext-link-type="uri" xlink:href="https://github.com/rrwick/Unicycler">https://github.com/rrwick/Unicycler</ext-link>, copy archived at <xref ref-type="bibr" rid="bib57">Wick, 2024</xref>) to generate long-read sequences. During the assembly process, sequence correction was performed using Pilon (version 1.22, <ext-link ext-link-type="uri" xlink:href="https://github.com/broadinstitute/pilon/wiki/Standard-Output">https://github.com/broadinstitute/pilon/wiki/Standard-Output</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://github.com/broadinstitute/pilon">https://github.com/broadinstitute/pilon</ext-link> copy archived at <xref ref-type="bibr" rid="bib54">Walker, 2021</xref>). Lastly, a complete genome with seamless chromosomes was obtained.</p><p>The CDSs of the strain genome were predicted using Glimmer (version 3.02, <ext-link ext-link-type="uri" xlink:href="http://ccb.jhu.edu/software/glimmer/index.shtml">http://ccb.jhu.edu/software/glimmer/index.shtml</ext-link>). The tRNA and rRNA genes were predicted using TRNAscan-SE (version 2.0, <ext-link ext-link-type="uri" xlink:href="http://trna.ucsc.edu/software/">http://trna.ucsc.edu/software/</ext-link>) and Barrnap (version 0.8, <ext-link ext-link-type="uri" xlink:href="https://github.com/tseemann/barrnap">https://github.com/tseemann/barrnap</ext-link>, copy archived at <xref ref-type="bibr" rid="bib45">Seemann, 2019</xref>), respectively. The functional annotation of all CDSs was performed using various databases, including Swiss-Prot Database (<ext-link ext-link-type="uri" xlink:href="https://web.expasy.org/docs/swiss-prot_guideline.html">https://web.expasy.org/docs/swiss-prot_guideline.html</ext-link>), Pfam Database (<ext-link ext-link-type="uri" xlink:href="http://pfam.xfam.org/">http://pfam.xfam.org/</ext-link>), EggNOG Database (<ext-link ext-link-type="uri" xlink:href="http://eggnog.embl.de/">http://eggnog.embl.de/</ext-link>), GO Database (<ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org/">http://www.geneontology.org/</ext-link>), and KEGG Database (<ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg/">http://www.genome.jp/kegg/</ext-link>). The circular map of the strain genome was generated using CGView (version 2, <ext-link ext-link-type="uri" xlink:href="http://wishart.biology.ualberta.ca/cgview/">http://wishart.biology.ualberta.ca/cgview/</ext-link>) (<xref ref-type="bibr" rid="bib50">Stothard and Wishart, 2005</xref>).</p></sec><sec id="s4-9"><title>Comparative genomic analysis</title><p>To elucidate the phylogenetic relationships of the strain from a whole-genome perspective, a phylogenetic tree based on the whole genome was constructed using the Type (Strain) Genome Server (TYGS) online (<ext-link ext-link-type="uri" xlink:href="https://ggdc.dsmz.de/">https://ggdc.dsmz.de/</ext-link>) (<xref ref-type="bibr" rid="bib32">Meier-Kolthoff et al., 2022</xref>). The ANI values of the strain genome to the reference strain genome were then calculated using the JSpeciesWS online service (<xref ref-type="bibr" rid="bib41">Richter et al., 2016</xref>), and a heatmap was generated using TBtools (version 1.113) (<xref ref-type="bibr" rid="bib6">Chen et al., 2020</xref>).</p></sec><sec id="s4-10"><title>In vivo safety evaluation of <italic>B. velezensis</italic> HBXN2020</title><p>Female specific-pathogen-free (SPF) C57BL/6 mice aged 6–8 weeks were purchased from the Animal Experimental Center of Huazhong Agricultural University. All mice experiments were conducted in the standard SPF facility of Huazhong Agricultural University, with 12 hr of light and 12 hr of darkness at a temperature of 25°C and ad libitum access to food and water. The use of animals in this experiment was approved by the Animal Care and Ethics Committee of Huazhong Agricultural University (Ethics Approval Number: HZAUMO-2023-0089).</p><p>Safety assay of <italic>B. velezensis</italic> HBXN2020 referred to the method described by <xref ref-type="bibr" rid="bib65">Zhou et al., 2022</xref>, with slight modifications. After a 7-day acclimation period (free access to water and food), mice were randomly divided into four treatment groups (n=5): low-dose <italic>B. velezensis</italic> HBXN2020 spores group (L-HBXN2020 group, 10<sup>7</sup> CFU/mouse), medium-dose <italic>B. velezensis</italic> HBXN2020 spores group (M-HBXN2020 group, 10<sup>8</sup> CFU/mouse), high-dose <italic>B. velezensis</italic> HBXN2020 spores group (H-HBXN2020 group, 10<sup>9</sup> CFU/mouse), and a control group. During the experimental period (15 days), mice were weighed and orally gavaged with their respective treatments once every 2 days. On day 15, all mice were euthanized, and blood, heart, liver, spleen, lung, kidney, ileum, cecum, and colon were collected. Blood samples were used for routine blood and biochemistry tests. Major organ tissues (heart, liver, spleen, lung, and kidney) and a 5 mm distal segment of the colon were used for histopathology. The remaining colonic tissues were rapidly frozen in liquid nitrogen and stored at −80°C for cytokine and tight junction protein expression analysis.</p></sec><sec id="s4-11"><title><italic>S.</italic> Typhimurium-infected mouse model</title><p>After 7 days of acclimation (free access to water and food), mice were randomly divided into five treatment groups (n=6): control group, HBXN2020 group, STm+PBS group, STm+HBXN2020 group, and STm+CIP group. The <italic>S</italic>. Typhimurium-infected model was performed as previously described (<xref ref-type="bibr" rid="bib49">Stecher et al., 2005</xref>), with slight modifications. On the first day of the experiment, all mice in the STm+PBS group, STm+HBXN2020 group, and STm+CIP group were orally inoculated with 200 μL (5×10<sup>7</sup> CFU/mouse) of STm. On days 1, 3, and 5 following STm infection, each mouse in the HBXN2020 group, STm+HBXN2020 group, and STm+CIP group received 200 μL (1×10<sup>8</sup> CFU/mouse) of <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin (1 mg/mL) via gavage administration, respectively. In contrast, the control group and STm+PBS group received 200 μL of sterile PBS by oral gavage. Fecal samples were collected daily following STm infection and resuspended in sterile PBS. The number of STm in mice feces from both the STm+PBS, STm+HBXN2020, and STm+CIP groups was then determined by spreading a serial 10-fold dilution on selective LB agar plates containing 50 µg/mL kanamycin. Throughout the entire experiment, the body weight, stool consistency, and fecal occult blood of all mice were monitored daily. As shown in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>, DAI was calculated by the sum of the scores from three parameters (<xref ref-type="bibr" rid="bib39">Praveschotinunt et al., 2019</xref>). On day 7 after STm infection, all mice were euthanized, their ileum, cecum, and colon were collected. The length of colon was measured, and a 5 mm distal segment of the colon was fixed in 4% paraformaldehyde for further histopathology. The remaining colon was then rapidly frozen in liquid nitrogen and stored at −80°C for cytokine and tight junction protein expression analysis. Then, the number of STm in the ileum, cecum, and colon was determined by spreading serial 10-fold dilutions on selective LB agar plates.</p><p>To investigate the prophylactic efficacy of <italic>B. velezensis</italic> HBXN2020 in ameliorating STm-infected, another independent experiment was conducted using 6-week-old female C57BL/6 mice (SPF). After a 7-day acclimation period, mice were randomly assigned to five groups (n=6): control group, HBXN2020 group, PBS +STm group, HBXN2020+STm group, and CIP+STm group. On days 1, 3, 5, and 7, each mouse in the HBXN2020 group, HBXN2020+STm group, and CIP+STm group received 200 μL (1×10<sup>8</sup> CFU/mouse) of <italic>B. velezensis</italic> HBXN2020 spores or ciprofloxacin (1 mg/mL) via gavage administration. Meanwhile, mice in the control group and PBS+STm group received 200 μL of sterile PBS by oral gavage. On day 7, all mice in the PBS+STm group, HBXN2020+STm group, and CIP+STm group were orally inoculated with 200 μL (5×10<sup>7</sup> CFU/mouse) of STm. Fecal samples were collected daily following STm infection from both groups and resuspended in sterile PBS. The number of STm in the feces of mice was then determined by spreading serial 10-fold dilutions on selective LB agar plates (50 µg/mL kanamycin). Throughout the entire experiment, the body weight and DAI scores of all mice were monitored daily. On day 12, all mice were euthanized, and the ileum, cecum, and colon were collected. The colon length was measured, and a 5 mm distal segment of the colon was fixed in 4% formalin for sectioning and staining. The remaining colon was stored at −80°C for future analysis. Lastly, the number of STm in the ileum, cecum, and colon was determined using a selective LB agar plate.</p></sec><sec id="s4-12"><title>Determination of cytokines and tight junction protein expression in colon tissue</title><p>Total RNA was extracted from colon tissues using TRIpure reagent (Aidlab, China), and cDNA was obtained using HiScript III RT SuperMix for qPCR (+gDNA wiper) (Vazyme, China). RT-qPCR for each gene was performed in triplicate using qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China). The relative expression level of cytokine and tight junction protein genes was calculated using the 2<sup>−ΔΔCt</sup> method with β-actin and GAPDH as reference genes. The primer sequences used in the RT-qPCR test are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-13"><title>Histopathology analysis</title><p>Colon tissue samples (0.5 cm) were fixed in 4% paraformaldehyde for 24 hr, and the fixed tissues were then embedded in paraffin and sectioned. The sections were stained with hematoxylin and eosin (H&amp;E) and observed and imaged using an optical microscope (Olympus Optical, Tokyo, Japan). The histopathological score included the degree of inflammatory infiltration, changes in crypt structures, and the presence or absence of ulceration and edema. The scoring criteria were determined as previously described (<xref ref-type="bibr" rid="bib58">Wu et al., 2022</xref>).</p></sec><sec id="s4-14"><title>16S rRNA gene sequencing and analysis</title><p>According to the manufacturer’s instructions, colon microbial community genomes were extracted using E.Z-N.A Stool DNA Kit (Omega; D4015-01), and quality was detected by 1% agarose gel electrophoresis. The 16S rRNA V3-V4 variable region was amplified by PCR using universal primers 338F (5 '- <named-content content-type="sequence">ACTCCTACGGGGGGCAG</named-content>-3') and 806R (5 '- GACTACHVGGGTWTCTAAT-3'). The PCR products were examined by electrophoresis on 2% agarose gels and then purified with the AxyPrep DNA gel extraction kit (Axygen Biosciences, USA). A sequencing library was constructed using the NEXTFLEX Rapid DNA-Seq Kit, and sequencing was performed using the Illumina MiSeq platform. Raw reads were quality evaluated and filtered by fastp (version 0.20.0) and merged using FLASH (version 1.2.7). The optimized sequences were clustered into operational taxonomic units (OTUs) based on 97% sequence similarity using UPARSE (version 7.1). The representative sequences of each OTU was classified by RDP classifier (version 2.2; confidence threshold value, 0.7). Alpha diversity was assessed using the ACE, Chao, Shannon, and Simpson indices. The β diversity analysis was performed using Bray-Curtis distances and visualized through PCA. LefSe was used to identify differential microbiota between groups.</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad Prism 8.3.0 (GraphPad Software, San Diego, CA, USA) and Excel (Microsoft, Redmond, WA, USA). Data are presented as mean ± standard error of the mean (SEM). Differences between two groups were evaluated using two-tailed unpaired Student’s t-test, and all other comparisons were conducted using one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. For all analyses, significance differences are denoted as: *, p&lt;0.05, **, p&lt;0.01, and ***, p&lt;0.001.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The use of all animals in this experiment was approved by the Animal Care and Ethics Committee of Huazhong Agricultural University (Ethics Approval Number: HZAUMO-2023-0089).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Determination of antibacterial activity of different <italic>Bacillus.</italic></title></caption><media xlink:href="elife-93423-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>HBXN2020 genome features and clusters of secondary metabolic synthesis genes.</title><p>(a) HBXN2020 genome features. (b) Clusters of secondary metabolic synthesis genes in HBXN2020.</p></caption><media xlink:href="elife-93423-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>The bacterial strains, RT-qPCR primers, and disease activity index scoring schemes in this study.</title><p>(a) The bacterial strains used in this study. (b) The primer sequences used for the RT-qPCR. (c) Disease activity index (DAI) parameters and their associated scoring schemes.</p></caption><media xlink:href="elife-93423-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-93423-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Whole genome sequencing data of Bacillus velezensis have been deposited in NCBI GenBank under accession code CP119399.1.16s rRNA sequencing data of mice have been deposited in NCBI under the accession code PRJNA1150571.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LK</given-names></name><name><surname>Qian</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Bacillus velezensis strain HBXN2020 chromosome, complete genome</data-title><source>NCBI GenBank</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/CP119399.1?report=genbank&amp;to=3929792">CP119399.1</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Effect of probiotic Bacillus on the gut microbiota of mice</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/bioproject/PRJNA1150571">PRJNA1150571</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by grants from the National Program on Key Research Project of China (2021YFD1800300, 2022YFD1800800), 'Yingzi Tech &amp; Huazhong Agricultural University Intelligent Research Institute of Food Health' (No. IRIFH202209; IRIFH202301), and the Fundamental Research Funds for the Central Universities (2662016PY004).</p><p>RT-qPCR data were acquired at the National Key Laboratory of Agricultural Microbiology Core Facility.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdhul</surname><given-names>K</given-names></name><name><surname>Ganesh</surname><given-names>M</given-names></name><name><surname>Shanmughapriya</surname><given-names>S</given-names></name><name><surname>Vanithamani</surname><given-names>S</given-names></name><name><surname>Kanagavel</surname><given-names>M</given-names></name><name><surname>Anbarasu</surname><given-names>K</given-names></name><name><surname>Natarajaseenivasan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bacteriocinogenic potential of a probiotic strain Bacillus coagulans [BDU3] from Ngari</article-title><source>International Journal of Biological Macromolecules</source><volume>79</volume><fpage>800</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2015.06.005</pub-id><pub-id pub-id-type="pmid">26054664</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazzoni</surname><given-names>G</given-names></name><name><surname>Martinez-Estrada</surname><given-names>OM</given-names></name><name><surname>Orsenigo</surname><given-names>F</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Citi</surname><given-names>S</given-names></name><name><surname>Dejana</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludin</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>20520</fpage><lpage>20526</lpage><pub-id pub-id-type="doi">10.1074/jbc.M905251199</pub-id><pub-id pub-id-type="pmid">10877843</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buddhasiri</surname><given-names>S</given-names></name><name><surname>Sukjoi</surname><given-names>C</given-names></name><name><surname>Kaewsakhorn</surname><given-names>T</given-names></name><name><surname>Nambunmee</surname><given-names>K</given-names></name><name><surname>Nakphaichit</surname><given-names>M</given-names></name><name><surname>Nitisinprasert</surname><given-names>S</given-names></name><name><surname>Thiennimitr</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Anti-inflammatory effect of probiotic <italic>Limosilactobacillus reuteri</italic> KUB-AC5 against <italic>Salmonella</italic> infection in a mouse colitis model</article-title><source>Frontiers in Microbiology</source><volume>12</volume><elocation-id>716761</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.716761</pub-id><pub-id pub-id-type="pmid">34497597</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Depommier</surname><given-names>C</given-names></name><name><surname>Derrien</surname><given-names>M</given-names></name><name><surname>Everard</surname><given-names>A</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>19</volume><fpage>625</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/s41575-022-00631-9</pub-id><pub-id pub-id-type="pmid">35641786</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5783</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13727-9</pub-id><pub-id pub-id-type="pmid">31857577</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Thomas</surname><given-names>HR</given-names></name><name><surname>Frank</surname><given-names>MH</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TBtools: an integrative toolkit developed for interactive analyses of big biological data</article-title><source>Molecular Plant</source><volume>13</volume><fpage>1194</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1016/j.molp.2020.06.009</pub-id><pub-id pub-id-type="pmid">32585190</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Polyphenols from blueberries modulate inflammation cytokines in LPS-induced RAW264.7 macrophages</article-title><source>International Journal of Biological Macromolecules</source><volume>69</volume><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2014.05.071</pub-id><pub-id pub-id-type="pmid">24905959</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="book"><person-group person-group-type="author"><collab>CLSI</collab></person-group><year iso-8601-date="2018">2018</year><source>Performance Standards for Antimicrobial Disk Susceptibility Tests, M02</source><publisher-name>Clinical and Laboratory Standards Institute</publisher-name></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristofori</surname><given-names>F</given-names></name><name><surname>Dargenio</surname><given-names>VN</given-names></name><name><surname>Dargenio</surname><given-names>C</given-names></name><name><surname>Miniello</surname><given-names>VL</given-names></name><name><surname>Barone</surname><given-names>M</given-names></name><name><surname>Francavilla</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>578386</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.578386</pub-id><pub-id pub-id-type="pmid">33717063</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crits-Christoph</surname><given-names>A</given-names></name><name><surname>Hallowell</surname><given-names>HA</given-names></name><name><surname>Koutouvalis</surname><given-names>K</given-names></name><name><surname>Suez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Good microbes, bad genes? The dissemination of antimicrobial resistance in the human microbiome</article-title><source>Gut Microbes</source><volume>14</volume><elocation-id>2055944</elocation-id><pub-id pub-id-type="doi">10.1080/19490976.2022.2055944</pub-id><pub-id pub-id-type="pmid">35332832</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>AS</given-names></name><name><surname>Sadoff</surname><given-names>JC</given-names></name><name><surname>Kelly</surname><given-names>N</given-names></name><name><surname>Bernton</surname><given-names>E</given-names></name><name><surname>Gemski</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection</article-title><source>The Journal of Experimental Medicine</source><volume>169</volume><fpage>2021</fpage><lpage>2027</lpage><pub-id pub-id-type="doi">10.1084/jem.169.6.2021</pub-id><pub-id pub-id-type="pmid">2659724</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Proinflammatory cytokines</article-title><source>Chest</source><volume>118</volume><fpage>503</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1378/chest.118.2.503</pub-id><pub-id pub-id-type="pmid">10936147</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Kulyar</surname><given-names>MFEA</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Bhutta</surname><given-names>ZA</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effects of bacillus amyloliquefaciens TL106 isolated from tibetan pigs on probiotic potential and intestinal microbes in weaned piglets</article-title><source>Microbiology Spectrum</source><volume>10</volume><elocation-id>e0120521</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.01205-21</pub-id><pub-id pub-id-type="pmid">35080439</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>XC</given-names></name><name><surname>Li</surname><given-names>XX</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>FQ</given-names></name><name><surname>Qian</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Exploiting broad-spectrum chimeric lysin to cooperate with mupirocin against <italic>Staphylococcus aureus</italic>-induced skin infections and delay the development of mupirocin resistance</article-title><source>Microbiology Spectrum</source><volume>11</volume><elocation-id>e0505022</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.05050-22</pub-id><pub-id pub-id-type="pmid">37125939</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fàbrega</surname><given-names>A</given-names></name><name><surname>Vila</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title><italic>Salmonella enterica</italic> serovar Typhimurium skills to succeed in the host: virulence and regulation</article-title><source>Clinical Microbiology Reviews</source><volume>26</volume><fpage>308</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1128/CMR.00066-12</pub-id><pub-id pub-id-type="pmid">23554419</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferri</surname><given-names>M</given-names></name><name><surname>Ranucci</surname><given-names>E</given-names></name><name><surname>Romagnoli</surname><given-names>P</given-names></name><name><surname>Giaccone</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antimicrobial resistance: A global emerging threat to public health systems</article-title><source>Critical Reviews in Food Science and Nutrition</source><volume>57</volume><fpage>2857</fpage><lpage>2876</lpage><pub-id pub-id-type="doi">10.1080/10408398.2015.1077192</pub-id><pub-id pub-id-type="pmid">26464037</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Fitness Trade-offs in phage cocktail-resistant <italic>Salmonella enterica</italic> serovar enteritidis results in increased antibiotic susceptibility and reduced virulence</article-title><source>Microbiology Spectrum</source><volume>10</volume><elocation-id>e0291422</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.02914-22</pub-id><pub-id pub-id-type="pmid">36165776</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gou</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zu</surname><given-names>M</given-names></name><name><surname>Yi</surname><given-names>S</given-names></name><name><surname>Ying</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>F</given-names></name><name><surname>Ke</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapy</article-title><source>Acta Pharmaceutica Sinica. B</source><volume>12</volume><fpage>406</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.07.001</pub-id><pub-id pub-id-type="pmid">35127395</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>SB</given-names></name><name><surname>Zhao</surname><given-names>LN</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>SC</given-names></name><name><surname>Sun</surname><given-names>JR</given-names></name><name><surname>Huang</surname><given-names>JF</given-names></name><name><surname>Li</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Potential probiotic attributes of a new strain of Bacillus coagulans CGMCC 9951 isolated from healthy piglet feces</article-title><source>World Journal of Microbiology &amp; Biotechnology</source><volume>31</volume><fpage>851</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1007/s11274-015-1838-x</pub-id><pub-id pub-id-type="pmid">25752235</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Kamada</surname><given-names>N</given-names></name><name><surname>Mikami</surname><given-names>Y</given-names></name><name><surname>Matsuoka</surname><given-names>K</given-names></name><name><surname>Hisamatsu</surname><given-names>T</given-names></name><name><surname>Hibi</surname><given-names>T</given-names></name><name><surname>Roers</surname><given-names>A</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Ohteki</surname><given-names>T</given-names></name><name><surname>Yoshimura</surname><given-names>A</given-names></name><name><surname>Kanai</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice</article-title><source>Cell Host &amp; Microbe</source><volume>13</volume><fpage>711</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2013.05.013</pub-id><pub-id pub-id-type="pmid">23768495</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herp</surname><given-names>S</given-names></name><name><surname>Brugiroux</surname><given-names>S</given-names></name><name><surname>Garzetti</surname><given-names>D</given-names></name><name><surname>Ring</surname><given-names>D</given-names></name><name><surname>Jochum</surname><given-names>LM</given-names></name><name><surname>Beutler</surname><given-names>M</given-names></name><name><surname>Eberl</surname><given-names>C</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Gerlach</surname><given-names>RG</given-names></name><name><surname>Ruscheweyh</surname><given-names>HJ</given-names></name><name><surname>Huson</surname><given-names>D</given-names></name><name><surname>Sellin</surname><given-names>ME</given-names></name><name><surname>Slack</surname><given-names>E</given-names></name><name><surname>Hanson</surname><given-names>B</given-names></name><name><surname>Loy</surname><given-names>A</given-names></name><name><surname>Baines</surname><given-names>JF</given-names></name><name><surname>Rausch</surname><given-names>P</given-names></name><name><surname>Basic</surname><given-names>M</given-names></name><name><surname>Bleich</surname><given-names>A</given-names></name><name><surname>Berry</surname><given-names>D</given-names></name><name><surname>Stecher</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mucispirillum schaedleri Antagonizes <italic>Salmonella</italic> virulence to protect mice against colitis</article-title><source>Cell Host &amp; Microbe</source><volume>25</volume><fpage>681</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.03.004</pub-id><pub-id pub-id-type="pmid">31006637</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>FC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Upregulation of <italic>Salmonella</italic>-induced IL-6 production in Caco-2 cells by PJ-34, PARP-1 inhibitor: involvement of PI3K, p38 MAPK, ERK, JNK, and NF-kappaB</article-title><source>Mediators of Inflammation</source><volume>2009</volume><elocation-id>103890</elocation-id><pub-id pub-id-type="doi">10.1155/2009/103890</pub-id><pub-id pub-id-type="pmid">20204057</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>BR</given-names></name><name><surname>Tuladhar</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Zalduondo</surname><given-names>L</given-names></name><name><surname>Samir</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Sundaram</surname><given-names>B</given-names></name><name><surname>Banoth</surname><given-names>B</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Schreiner</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes</article-title><source>Cell</source><volume>184</volume><fpage>149</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id><pub-id pub-id-type="pmid">33278357</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katiyo</surname><given-names>S</given-names></name><name><surname>Muller-Pebody</surname><given-names>B</given-names></name><name><surname>Minaji</surname><given-names>M</given-names></name><name><surname>Powell</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>AP</given-names></name><name><surname>Pinna</surname><given-names>E</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Godbole</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epidemiology and outcomes of nontyphoidal <italic>Salmonella</italic> bacteremias from England</article-title><source>Journal of Clinical Microbiology</source><volume>57</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1128/JCM.01189-18</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>H</given-names></name><name><surname>Gupta</surname><given-names>T</given-names></name><name><surname>Kapila</surname><given-names>S</given-names></name><name><surname>Kapila</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Protective effects of potential probiotic Lactobacillus rhamnosus (MTCC-5897) fermented whey on reinforcement of intestinal epithelial barrier function in a colitis-induced murine model</article-title><source>Food &amp; Function</source><volume>12</volume><fpage>6102</fpage><lpage>6116</lpage><pub-id pub-id-type="doi">10.1039/d0fo02641g</pub-id><pub-id pub-id-type="pmid">34047732</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotas</surname><given-names>ME</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Homeostasis, inflammation, and disease susceptibility</article-title><source>Cell</source><volume>160</volume><fpage>816</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.02.010</pub-id><pub-id pub-id-type="pmid">25723161</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Qamar</surname><given-names>H</given-names></name><name><surname>Mehmood</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Probiotics isolated from yaks improves the growth performance, antioxidant activity, and cytokines related to immunity and inflammation in mice</article-title><source>Microbial Cell Factories</source><volume>18</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.1186/s12934-019-1161-6</pub-id><pub-id pub-id-type="pmid">31217027</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Huo</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Man</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title><italic>Lactobacillus plantarum</italic> J26 alleviating alcohol-induced liver inflammation by maintaining the intestinal barrier and regulating MAPK signaling pathways</article-title><source>Nutrients</source><volume>15</volume><elocation-id>190</elocation-id><pub-id pub-id-type="doi">10.3390/nu15010190</pub-id><pub-id pub-id-type="pmid">36615846</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Chu</surname><given-names>D</given-names></name><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cytokines: from clinical significance to quantification</article-title><source>Advanced Science</source><volume>8</volume><elocation-id>e2004433</elocation-id><pub-id pub-id-type="doi">10.1002/advs.202004433</pub-id><pub-id pub-id-type="pmid">34114369</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title><italic>Lactobacillus plantarum</italic> 23-1 improves intestinal inflammation and barrier function through the TLR4/NF-κB signaling pathway in obese mice</article-title><source>Food &amp; Function</source><volume>13</volume><fpage>5971</fpage><lpage>5986</lpage><pub-id pub-id-type="doi">10.1039/D1FO04316A</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maloy</surname><given-names>KJ</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Intestinal homeostasis and its breakdown in inflammatory bowel disease</article-title><source>Nature</source><volume>474</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nature10208</pub-id><pub-id pub-id-type="pmid">21677746</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier-Kolthoff</surname><given-names>JP</given-names></name><name><surname>Carbasse</surname><given-names>JS</given-names></name><name><surname>Peinado-Olarte</surname><given-names>RL</given-names></name><name><surname>Göker</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>TYGS and LPSN: a database tandem for fast and reliable genome-based classification and nomenclature of prokaryotes</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D801</fpage><lpage>D807</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab902</pub-id><pub-id pub-id-type="pmid">34634793</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Munusamy</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>Y-C</given-names></name><name><surname>Muthuvelu</surname><given-names>S</given-names></name><name><surname>Hashim</surname><given-names>R</given-names></name><name><surname>Chien</surname><given-names>S-L</given-names></name><name><surname>Wong</surname><given-names>M-K</given-names></name><name><surname>Khairuddin</surname><given-names>NA</given-names></name><name><surname>Podin</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>PS-T</given-names></name><name><surname>Ng</surname><given-names>DC-E</given-names></name><name><surname>Ooi</surname><given-names>M-H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Invasive <italic>Salmonella</italic> infections among children in Bintulu, Sarawak, Malaysian Borneo: a 6-year retrospective review</article-title><source>BMC Infectious Diseases</source><volume>19</volume><elocation-id>330</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-3963-x</pub-id><pub-id pub-id-type="pmid">30999894</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohland</surname><given-names>CL</given-names></name><name><surname>Macnaughton</surname><given-names>WK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Probiotic bacteria and intestinal epithelial barrier function</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>298</volume><fpage>G807</fpage><lpage>G819</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00243.2009</pub-id><pub-id pub-id-type="pmid">20299599</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouattara</surname><given-names>HG</given-names></name><name><surname>Reverchon</surname><given-names>S</given-names></name><name><surname>Niamke</surname><given-names>SL</given-names></name><name><surname>Nasser</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of the synthesis of pulp degrading enzymes in Bacillus isolated from cocoa fermentation</article-title><source>Food Microbiology</source><volume>63</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.fm.2016.12.004</pub-id><pub-id pub-id-type="pmid">28040177</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Rutz</surname><given-names>S</given-names></name><name><surname>Crellin</surname><given-names>NK</given-names></name><name><surname>Valdez</surname><given-names>PA</given-names></name><name><surname>Hymowitz</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation and functions of the IL-10 family of cytokines in inflammation and disease</article-title><source>Annual Review of Immunology</source><volume>29</volume><fpage>71</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-031210-101312</pub-id><pub-id pub-id-type="pmid">21166540</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozer</surname><given-names>J</given-names></name><name><surname>Ratner</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Bailey</surname><given-names>W</given-names></name><name><surname>Schomaker</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The current state of serum biomarkers of hepatotoxicity</article-title><source>Toxicology</source><volume>245</volume><fpage>194</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2007.11.021</pub-id><pub-id pub-id-type="pmid">18291570</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulson</surname><given-names>JA</given-names></name><name><surname>Zaoutis</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics</article-title><source>Pediatrics</source><volume>136</volume><fpage>e1670</fpage><lpage>e1677</lpage><pub-id pub-id-type="doi">10.1542/peds.2015-3630</pub-id><pub-id pub-id-type="pmid">26574594</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praveschotinunt</surname><given-names>P</given-names></name><name><surname>Duraj-Thatte</surname><given-names>AM</given-names></name><name><surname>Gelfat</surname><given-names>I</given-names></name><name><surname>Bahl</surname><given-names>F</given-names></name><name><surname>Chou</surname><given-names>DB</given-names></name><name><surname>Joshi</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Engineered <italic>E. coli</italic> Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5580</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13336-6</pub-id><pub-id pub-id-type="pmid">31811125</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyman</surname><given-names>M</given-names></name><name><surname>van Houten</surname><given-names>MA</given-names></name><name><surname>Watson</surname><given-names>RL</given-names></name><name><surname>Chu</surname><given-names>MLJN</given-names></name><name><surname>Arp</surname><given-names>K</given-names></name><name><surname>de Waal</surname><given-names>WJ</given-names></name><name><surname>Schiering</surname><given-names>I</given-names></name><name><surname>Plötz</surname><given-names>FB</given-names></name><name><surname>Willems</surname><given-names>RJL</given-names></name><name><surname>van Schaik</surname><given-names>W</given-names></name><name><surname>Sanders</surname><given-names>EAM</given-names></name><name><surname>Bogaert</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>893</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28525-z</pub-id><pub-id pub-id-type="pmid">35173154</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>M</given-names></name><name><surname>Rosselló-Móra</surname><given-names>R</given-names></name><name><surname>Oliver Glöckner</surname><given-names>F</given-names></name><name><surname>Peplies</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>JSpeciesWS: a web server for prokaryotic species circumscription based on pairwise genome comparison</article-title><source>Bioinformatics</source><volume>32</volume><fpage>929</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv681</pub-id><pub-id pub-id-type="pmid">26576653</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>ME</given-names></name><name><surname>Akkermans</surname><given-names>LMA</given-names></name><name><surname>Haller</surname><given-names>D</given-names></name><name><surname>Hammerman</surname><given-names>C</given-names></name><name><surname>Heimbach</surname><given-names>J</given-names></name><name><surname>Hörmannsperger</surname><given-names>G</given-names></name><name><surname>Huys</surname><given-names>G</given-names></name><name><surname>Levy</surname><given-names>DD</given-names></name><name><surname>Lutgendorff</surname><given-names>F</given-names></name><name><surname>Mack</surname><given-names>D</given-names></name><name><surname>Phothirath</surname><given-names>P</given-names></name><name><surname>Solano-Aguilar</surname><given-names>G</given-names></name><name><surname>Vaughan</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Safety assessment of probiotics for human use</article-title><source>Gut Microbes</source><volume>1</volume><fpage>164</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.4161/gmic.1.3.12127</pub-id><pub-id pub-id-type="pmid">21327023</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraiva</surname><given-names>M</given-names></name><name><surname>Vieira</surname><given-names>P</given-names></name><name><surname>O’Garra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Biology and therapeutic potential of interleukin-10</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>e20190418</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20190418</pub-id><pub-id pub-id-type="pmid">31611251</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>BM</given-names></name><name><surname>Paduro</surname><given-names>CA</given-names></name><name><surname>Salazar</surname><given-names>GA</given-names></name><name><surname>Salazar-Echegarai</surname><given-names>FJ</given-names></name><name><surname>Sebastián</surname><given-names>VP</given-names></name><name><surname>Riedel</surname><given-names>CA</given-names></name><name><surname>Kalergis</surname><given-names>AM</given-names></name><name><surname>Alvarez-Lobos</surname><given-names>M</given-names></name><name><surname>Bueno</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Potential Role of <italic>Salmonella</italic> infection in the onset of inflammatory bowel diseases</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>191</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00191</pub-id><pub-id pub-id-type="pmid">28293241</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Seemann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Barrnap</data-title><version designator="swh:1:rev:acf3198a2e671f79107d8221bc32c110a6272ca6">swh:1:rev:acf3198a2e671f79107d8221bc32c110a6272ca6</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:8417002123a3eae095b13e82bbbdf9ed51037afd;origin=https://github.com/tseemann/barrnap;visit=swh:1:snp:71c750fa91f52c6c2c2781e16588408a3d9a4dd0;anchor=swh:1:rev:acf3198a2e671f79107d8221bc32c110a6272ca6">https://archive.softwareheritage.org/swh:1:dir:8417002123a3eae095b13e82bbbdf9ed51037afd;origin=https://github.com/tseemann/barrnap;visit=swh:1:snp:71c750fa91f52c6c2c2781e16588408a3d9a4dd0;anchor=swh:1:rev:acf3198a2e671f79107d8221bc32c110a6272ca6</ext-link></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Štefanič</surname><given-names>P</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>B</given-names></name><name><surname>Mandic-Mulec</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Annulment of bacterial antagonism improves plant beneficial activity of a bacillus velezensis consortium</article-title><source>Applied and Environmental Microbiology</source><volume>88</volume><elocation-id>e0024022</elocation-id><pub-id pub-id-type="doi">10.1128/aem.00240-22</pub-id><pub-id pub-id-type="pmid">35380452</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Inverso</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Bartels</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Abdul Pari</surname><given-names>AA</given-names></name><name><surname>Gengenbacher</surname><given-names>N</given-names></name><name><surname>Besemfelder</surname><given-names>E</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Augustin</surname><given-names>HG</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Endothelial cell fitness dictates the source of regenerating liver vasculature</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>2497</fpage><lpage>2508</lpage><pub-id pub-id-type="doi">10.1084/jem.20180008</pub-id><pub-id pub-id-type="pmid">30194265</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snydman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The safety of probiotics</article-title><source>Clinical Infectious Diseases</source><volume>46 Suppl 2</volume><fpage>S104</fpage><lpage>S111</lpage><pub-id pub-id-type="doi">10.1086/523331</pub-id><pub-id pub-id-type="pmid">18181712</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stecher</surname><given-names>B</given-names></name><name><surname>Macpherson</surname><given-names>AJ</given-names></name><name><surname>Hapfelmeier</surname><given-names>S</given-names></name><name><surname>Kremer</surname><given-names>M</given-names></name><name><surname>Stallmach</surname><given-names>T</given-names></name><name><surname>Hardt</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Comparison of <italic>Salmonella enterica</italic> serovar Typhimurium colitis in germfree mice and mice pretreated with streptomycin</article-title><source>Infection and Immunity</source><volume>73</volume><fpage>3228</fpage><lpage>3241</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.6.3228-3241.2005</pub-id><pub-id pub-id-type="pmid">15908347</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stothard</surname><given-names>P</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Circular genome visualization and exploration using CGView</article-title><source>Bioinformatics</source><volume>21</volume><fpage>537</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti054</pub-id><pub-id pub-id-type="pmid">15479716</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Xing</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Quercetin prevents ethanol-induced dyslipidemia and mitochondrial oxidative damage</article-title><source>Food and Chemical Toxicology</source><volume>50</volume><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2012.02.008</pub-id><pub-id pub-id-type="pmid">22365892</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>O</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oral delivery of <italic>Bacillus subtilis</italic> spores expressing cysteine protease of Clonorchis sinensis to grass carp (Ctenopharyngodon idellus): Induces immune responses and has no damage on liver and intestine function</article-title><source>Fish &amp; Shellfish Immunology</source><volume>64</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2017.03.030</pub-id><pub-id pub-id-type="pmid">28323213</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unban</surname><given-names>K</given-names></name><name><surname>Kochasee</surname><given-names>P</given-names></name><name><surname>Shetty</surname><given-names>K</given-names></name><name><surname>Khanongnuch</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tannin-tolerant and extracellular tannase producing <italic>Bacillus</italic> isolated from traditional fermented tea leaves and their probiotic functional properties</article-title><source>Foods</source><volume>9</volume><elocation-id>490</elocation-id><pub-id pub-id-type="doi">10.3390/foods9040490</pub-id><pub-id pub-id-type="pmid">32295023</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Pilon</data-title><version designator="swh:1:rev:3d36fdca76d200a2dacf1114c8ce1a0ae5a30911">swh:1:rev:3d36fdca76d200a2dacf1114c8ce1a0ae5a30911</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:950ff836f5d7e64f541021e0dffc2619c640f36f;origin=https://github.com/broadinstitute/pilon;visit=swh:1:snp:1e9f99d33df90c4a72c8c57ceca7f4cd09bb1e53;anchor=swh:1:rev:3d36fdca76d200a2dacf1114c8ce1a0ae5a30911">https://archive.softwareheritage.org/swh:1:dir:950ff836f5d7e64f541021e0dffc2619c640f36f;origin=https://github.com/broadinstitute/pilon;visit=swh:1:snp:1e9f99d33df90c4a72c8c57ceca7f4cd09bb1e53;anchor=swh:1:rev:3d36fdca76d200a2dacf1114c8ce1a0ae5a30911</ext-link></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Ning</surname><given-names>K</given-names></name><name><surname>Xiang</surname><given-names>JY</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Combination of probiotics with different functions alleviate DSS-induced colitis by regulating intestinal microbiota, IL-10, and barrier function</article-title><source>Applied Microbiology and Biotechnology</source><volume>104</volume><fpage>335</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-10259-6</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gou</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The interplay between herbal medicines and gut microbiota in metabolic diseases</article-title><source>Frontiers in Pharmacology</source><volume>14</volume><elocation-id>1105405</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2023.1105405</pub-id><pub-id pub-id-type="pmid">37033634</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Unicycler</data-title><version designator="swh:1:rev:d153f67d6f626176c100724600104ade4f6d7a2e">swh:1:rev:d153f67d6f626176c100724600104ade4f6d7a2e</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:16431772fbc8a6c1d6af643275ef29c15f217957;origin=https://github.com/rrwick/Unicycler;visit=swh:1:snp:666e30dc1995697ac0d27bfbe643187874c85b9b;anchor=swh:1:rev:d153f67d6f626176c100724600104ade4f6d7a2e">https://archive.softwareheritage.org/swh:1:dir:16431772fbc8a6c1d6af643275ef29c15f217957;origin=https://github.com/rrwick/Unicycler;visit=swh:1:snp:666e30dc1995697ac0d27bfbe643187874c85b9b;anchor=swh:1:rev:d153f67d6f626176c100724600104ade4f6d7a2e</ext-link></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Johnston</surname><given-names>LJ</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Limosilactobacillus reuteri SLZX19-12 protects the colon from infection by enhancing stability of the gut microbiota and barrier integrity and reducing inflammation</article-title><source>Microbiology Spectrum</source><volume>10</volume><elocation-id>e0212421</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.02124-21</pub-id><pub-id pub-id-type="pmid">35658572</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WH</given-names></name><name><surname>Westman</surname><given-names>JS</given-names></name><name><surname>Heithoff</surname><given-names>DM</given-names></name><name><surname>Sperandio</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>JW</given-names></name><name><surname>Mahan</surname><given-names>MJ</given-names></name><name><surname>Marth</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neu3 neuraminidase induction triggers intestinal inflammation and colitis in a model of recurrent human food-poisoning</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2100937118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2100937118</pub-id><pub-id pub-id-type="pmid">34266954</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Population genetic structure and selection signature analysis of beijing black pig</article-title><source>Frontiers in Genetics</source><volume>13</volume><elocation-id>860669</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.860669</pub-id><pub-id pub-id-type="pmid">35401688</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Tao</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Characteristics and application of a novel species of Bacillus: Bacillus velezensis</article-title><source>ACS Chemical Biology</source><volume>13</volume><fpage>500</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00874</pub-id><pub-id pub-id-type="pmid">29309732</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dietary effects of <italic>Bacillus subtilis</italic> fmbj on the antioxidant capacity of broilers at an early age</article-title><source>Poultry Science</source><volume>96</volume><fpage>3564</fpage><lpage>3573</lpage><pub-id pub-id-type="doi">10.3382/ps/pex172</pub-id><pub-id pub-id-type="pmid">28938766</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>DX</given-names></name><name><surname>Kang</surname><given-names>YH</given-names></name><name><surname>Zhan</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>ZL</given-names></name><name><surname>Jin</surname><given-names>SN</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>CF</given-names></name><name><surname>Wang</surname><given-names>GQ</given-names></name><name><surname>Shan</surname><given-names>XF</given-names></name><name><surname>Qian</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Effect of bacillus velezensis on aeromonas veronii-induced intestinal mucosal barrier function damage and inflammation in crucian carp (Carassius auratus)</article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>2663</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02663</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Probiotic <italic>Bacillus subtilis</italic> LF11 protects intestinal epithelium against <italic>Salmonella</italic> infection</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>12</volume><elocation-id>837886</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.837886</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>3432</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31171-0</pub-id><pub-id pub-id-type="pmid">35701435</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zihni</surname><given-names>C</given-names></name><name><surname>Mills</surname><given-names>C</given-names></name><name><surname>Matter</surname><given-names>K</given-names></name><name><surname>Balda</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tight junctions: from simple barriers to multifunctional molecular gates</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>17</volume><fpage>564</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.80</pub-id><pub-id pub-id-type="pmid">27353478</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.93423.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kana</surname><given-names>Bavesh D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of the Witwatersrand</institution><country>South Africa</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>In this <bold>useful</bold> study, Wang and colleagues investigate the potential probiotic effects of Bacillus velezensis in a murine model. They provide <bold>convincing</bold> evidence that B. velezensis limits the growth of <italic>Salmonella</italic> typhimurium in lab culture and in mice, together with beneficial effects on the microbiota. The overall presentation of the manuscript has improved and the work will be of interest to infectious disease researchers.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.93423.4.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Wang and colleagues presented an investigation of pig-origin bacteria Bacillus velezensis HBXN2020, for its released genome sequence, in vivo safety issue, probiotic effects in vitro, and protection against <italic>Salmonella</italic> infection in a murine model. Various techniques and assays are performed; the main results are all descriptive, without new insight advancing the field or a mechanistic understanding of the observed protection.</p><p>Strengths:</p><p>An extensive study on the probiotic properties of the Bacillus velezensis strain HBXN2020</p><p>Weaknesses:</p><p>The main results are descriptive without mechanistic insight. Additionally, most of the results and analysis parts are separated without a link or a story-telling way to deliver a concise message.</p><p>Now the manuscript has made appropriate and considerable improvements.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.93423.4.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Linkang</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Haiyan</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xinxin</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Mengyuan</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Dongyang</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Dayue</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Zhixuan</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiangmin</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>Ping</given-names></name><role specific-use="author">Author</role><aff><institution>Huazhong Agricultural University</institution><addr-line><named-content content-type="city">Wuhan</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>Wang and colleagues presented an investigation of pig-origin bacteria Bacillus velezensis HBXN2020, for its released genome sequence, in vivo safety issue, probiotic effects in vitro, and protection against <italic>Salmonella</italic> infection in a murine model. Various techniques and assays are performed; the main results are all descriptive, without new insight advancing the field or a mechanistic understanding of the observed protection.</p></disp-quote><p>Thank you very much for your reading and comments our manuscript.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>An extensive study on probiotic property of the Bacillus velezensis strain HBXN2020</p></disp-quote><p>Thank you very much for your reading and comments our manuscript.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The main results are descriptive without mechanistic insight. Additionally, most of the results and analysis parts are separated without a link or a story-telling way to deliver a concise message.</p></disp-quote><p>Thank you for your comments and suggestions on our manuscript. In later work, we will focus on exploring the antibacterial substances and bactericidal mechanisms of <italic>B. velezensis</italic>. The manuscript results and analysis sections have been extensively revised. We appreciate your review and feedback.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>In this study, Wang and colleagues study the potential probiotic effects of Bacillus velezensis. Bacillus species have potential benefit to serve as probiotics due to their ability to form endospores and synthesize secondary metabolites. B. velezensis has been shown to have probiotic effects in plants and animals but data for human use are scarce, particularly with respect to <italic>Salmonella</italic>-induced colitis. In this work, the authors identify a strain of B. velezensis and test it for its ability to control colitis in mice.</p></disp-quote><p>Thanks for the constructive comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>Key findings:</p><p>(1) The authors sequence an isolate for B. velezensis - HBXN2020 and describe its genome (roughly 4 mb, 46% GC-content etc).</p></disp-quote><p>Thanks for the constructive comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>(2) The authors next describe the growth of this strain in broth culture and survival under acid and temperature stress. The susceptibility of HBXN2020 was tested against various antibiotics and against various pathogenic bacteria. In the case of the latter, the authors set out to determine if HBXN2020 could directly inhibit the growth of pathogenic bacteria. Convincing data, indicating that this is indeed the case, are presented.</p></disp-quote><p>Thanks for the constructive comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>(3) To determine the safety profile of BHXN2020 (for possible use as a probiotic), the authors infected the strain in mice and monitored weight, together with cytokine profiles. Infected mice displayed no significant weight loss and expression of inflammatory cytokines remained unchanged. Blood cell profiles of infected mice were consistent with that of uninfected mice. No significant differences in tissues, including the colon were observed.</p></disp-quote><p>Thanks for the constructive comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>(4) Next, the authors tested the ability to HBXN2020 to inhibit growth of <italic>Salmonella</italic> typhimurium (STm) and demonstrate that HBXN2020 inhibits STm in a dose dependent manner. Following this, the authors infect mice with STm to induce colitis and measure the ability of HBXN2020 to control colitis. The first outcome measure was a reduction in STm in faeces. Consistent with this, HBXN2020 reduced STm loads in the ileum, cecum, and colon. Colon length was also affected by HBXN2020 treatment. In addition, treatment with HBXN2020 reduced the appearance colon pathological features associated with colitis, together with a reduction in inflammatory cytokines.</p></disp-quote><p>Thanks for the constructive comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>(5) After noting the beneficial (and anti-inflammatory effects) of HBXN2020, the authors set out to investigate effects on microbiota during treatment. Using a variety of algorithms, the authors demonstrate that upon HXBN2020 treatment, microbiota composition is restored to levels akin to that seen in healthy mice.</p></disp-quote><p>Thanks for the constructive comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>(6) Finally, the authors assessed the effect of using HBXN2020 as prophylactic treatment for colitis by first treating mice with the spores and then infecting with STm. Their data indicate that treatment with HBXN2020 reduced colitis. A similar beneficial impact was seen with the gut microbiota.</p></disp-quote><p>Thanks for the constructive comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>(1) Good use of in vitro and animal models to demonstrate a beneficial probiotic effect.</p></disp-quote><p>Thank you very much for your reading and comments our manuscript.</p><disp-quote content-type="editor-comment"><p>(2) Most observations are supported using multiple approaches.</p></disp-quote><p>Thanks for the comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>(3) Mouse experiments are very convincing.</p></disp-quote><p>Thanks for the comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) Whilst a beneficial effect is observed, there no investigation of the mechanism that underpins this.</p></disp-quote><p>Thank you for pointing this out. We apologize for any inconvenience caused by the lack of mechanism research of the manuscript. In later work, we will focus on exploring the antibacterial substances and bactericidal mechanisms of <italic>B. velezensis</italic>. Thank you for your suggestions, and we hope our response has addressed your concerns.</p><disp-quote content-type="editor-comment"><p>(2) Mouse experiments would have benefited from the use of standard anti-inflammatory therapies to control colitis. That way the authors could compare their approach of using bacillus spores that current gold standard for treatment.</p></disp-quote><p>We gratefully appreciate for your valuable comments. The comments improve the quality and depth of manuscript. Based on your suggestion, we have supplemented this in the revised manuscript. We appreciate your review and feedback, and have marked the updated contents in the revised manuscript.</p><p>The updated contents were presented in line 198-378 in results section of the revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>The manuscript by Wang et al. investigates the effects of B. velezensis HBXN2020 in alleviating S. Typhimurium-induced mouse colitis. The results showed that B. velezensis HBXN2020 could alleviate bacterial colitis by enhancing intestinal homeostasis (decreasing harmful bacteria and enhancing the abundance of Lactobacillus and Akkermansia) and gut barrier integrity and reducing inflammation.</p></disp-quote><p>Thanks for the comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>B. velezensis HBXN2020 is a novel species of Bacillus that can produce a great variety of secondary metabolites and exhibit high antibacterial activity against several pathogens. B. velezensis HBXN2020 is able to form endospores and has strong anti-stress capabilities. B. velezensis HBXN2020 has a synergistic effect with other beneficial microorganisms, which can improve intestinal homeostasis.</p></disp-quote><p>Thanks for the comments and the positive reception of the manuscript.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>Few studies about the clinical application of Bacillus velezensis. Thus, more studies are still needed to explore the effectiveness of Bacillus velezensis before clinical application.</p></disp-quote><p>Thanks for your suggestion. This study serves as an exploratory investigation before the application of <italic>Bacillus velezensis</italic>. The main purpose of this study is to explore the potential of <italic>Bacillus velezensis</italic> in application. We appreciate your review and feedback and hope that our response adequately addresses your concerns.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Most of my previous comments are well addressed, here are a few examples.<ext-link ext-link-type="uri" xlink:href="https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo01017k">https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo01017k</ext-link> please replace &quot;colitis&quot; to a normal infection model. The current statement is incorrect.</p><p>While in my last comment, I requested a Colitis Mouse Model, which will well resemble the diarrhea disease caused by <italic>Salmonella</italic> in mammals. The available statement is not convincing, please check <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225501/,">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225501/,</ext-link></p></disp-quote><p>Thank you for your valuable suggestion. The comments improve the quality of manuscript. We have corrected this in the revised manuscript as suggested. We have marked the updated contents in the revised manuscript.</p><p>The updated contents were presented in line 2, 29, 38, 46, 48, 199, 204, 246, 248, 282, 307, 310, 316, 431, 433, 464, 466, 473, 494, 497, 499, 504, 513, 518, 525, 706, 710 and 735 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Certain parts remain to be overestimated, to my knowledge, the language and logical flow should be addressed thoroughly.</p><p>Here are suggestions to improve the logical flow of the manuscript.</p><p>(1) Probiotic sampling and isolation</p><p>(2) in vitro assessment</p><p>(3) genomic sequencing and in silico safety assessment (Crit Rev Food Sci Nutr. 2023;63(32):11244-11262), which should be included as a right ref.</p><p>(4) in vivo assay for safety evaluation, but not biosafety (it has a different meaning!!)</p><p>(5) infection model and protection assay.</p></disp-quote><p>We gratefully appreciate for your valuable comments. The comments improve the quality and depth of manuscript. According to your suggestion, we do our best to correct those problems in the revised manuscript. We would like to express our apologies once again and hope that the revised manuscript meets your expectations. We have marked the updated contents in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Also, please pay attention to the logical link or transition sentences between each part to connect the dots in each part.</p></disp-quote><p>We gratefully appreciate for your valuable comments. The comments improve the quality of manuscript. According to your suggestion, we have corrected this in the revised manuscript. We have marked the updated contents in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Finally, there are also lots of typos and errors, please improve through the text.</p><p>For example, Line 521. &quot;Stain&quot;, and more...</p></disp-quote><p>Thanks for pointing this out. Based on your suggestion, we have corrected in the revised manuscript. We have marked the updated contents in the revised manuscript.</p><p>The updated contents were presented in line 753, 1055, 1087 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>The revised manuscript by Wang and colleagues attempts to address concerns raised during the first round of review.</p><p>All minor comments have been addressed and in general, the major concerns have been partially addressed in the revised manuscript.</p><p>The outstanding concerns relate to the mechanistic basis of the observations. The authors made no attempt to address this in a meaningful manner. Secondly, the issue of comparing the responses to what would be standard therapy (such as anti-inflammatories) was also handled in a somewhat dismissive manner, referring to other ongoing/future work. The clinical utility of the findings are hard to ascertain if there is no comparison to the current gold standard therapeutic approach.</p><p>I have no further suggestions for the authors, save for those previously made.</p></disp-quote><p>Thank you for pointing this out. We apologize for any inconvenience caused by the lack of mechanism research of the manuscript. In later work, we will focus on exploring the antibacterial substances and bactericidal mechanisms of <italic>B. velezensis</italic>. Thank you for your suggestions, and we hope our response has addressed your concerns.</p><p>Secondly, About the comparative trial of oral <italic>bacillus</italic> spore treatment with the current gold standard for treatment, we have supplemented this in the revised manuscript. We appreciate your review and feedback, and have marked the updated contents in the revised manuscript.</p><p>The updated contents were presented in line 198-378 in results section of the revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>This is a revision, they have addressed all my concerns, and now it is acceptable.</p></disp-quote><p>Thank you very much for your comments and recognition of the manuscript.</p></body></sub-article></article>